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Depression is one of the top ten health problems in the world, affecting millions of 
Canadians. Research indicates that exercise is an effective treatment for depression but it 
is not clear on exactly how and why it works. Animal studies show that exercise 
improves the ability of the brain to function. It can even lead to new cell formation in a 
part of the brain called the hippocampus, which is important for memory processing. This 
study is investigating whether exercise may also improve hippocampal function in 
depressed humans. One way exercise may improve brain function is by normalizing 
levels of the hormone cortisol, and its toxic effects on the hippocampus. Exercise may 
also normalize levels of biochemical markers called cytokines involved in inflammation, 
while improving levels of growth factors important to brain cell function. This feasibility 
study aimed to develop protocols to investigate changes in hippocampal activity while 
participants are performing memory tests involving association of images and words in a 
functional magnetic resonance scanner before and after a 12 week exercise program. It 
also aimed to develop and validate protocols to measure changes in cortisol, cytokines 
and growth factors which are likely to be affected by exercise. Our preliminary imaging 
results revealed hippocampal dysregulation in the depressed brain, and biomarker 
analysis revealed abnormal concentrations of interleukin-6, vascular endothelial growth 
factor and salivary cortisol when compared to normal healthy controls. However, 
following the 12-week exercise program a more normalized pattern of hippocampal 
activation associated with successful memory encoding was observed. Additionally, 
biomarker concentrations either resembled or were closer to normal healthy values. Over 
the long term, the project arising from this feasibility study has the potential to provide a 
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tool to improve exercise prescription, to predict exercise responders and to guide 
development of combined treatment approaches related to biochemical markers in order 
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Chapter 1 Introduction 
 
1.1 Background to the study 
The effects of depression are profound and far-reaching, being the 3rd largest contributor 
to the burden of disease in high income and 7th in middle and low income countries 
(Lopez et al. 2006) and affecting millions of Canadians (Canada 2006) . Exercise has 
proven benefits in the treatment of depression (Blumenthal et al. 1999; Dunn et al. 2005), 
but there are several competing hypotheses in our understanding of its mechanism of 
action. Major Depressive Disorder (MDD) is associated with a wide array of 
physiological, psychological and cognitive symptoms particularly impairments in 
memory (Burt et al. 1995; Ilsley et al. 1995; Zakzanis et al. 1998; Airaksinen et al. 2004). 
Exercise has been shown to improve memory in people with MDD (Ernst et al. 2006; 
Cotman et al. 2007), suggesting an underlying mechanism that improves neural function 
however it has been difficult to ascribe the improvement to the physiological effects of 
exercise because of a lack of a physiological test that is clearly linked to improved neural 
function (Sperling et al. 2003; Fairhall et al. 2010). Recently, Fairhall (2010)  and 
colleagues were the first to demonstrate decreased activation of the hippocampus during 
the encoding phase of a memory task in depressed individuals compared to control 
subjects using functional magnetic resonance imaging (fMRI)(Fairhall et al. 2010). 
Researchers compared differences in hippocampal function (as opposed to volume 
differences) between eight people with MDD and eight age and gender matched controls.  
An associative memory task was designed based on work that showed robust modulation 
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of the right anterior hippocampus during the encoding of events that are subsequently 
successfully remembered (Sperling et al. 2003).  Likewise, pilot results confirmed robust 
activation in the right hippocampus during encoding.  Controls showed the predicted 
pattern of increased activation in the right anterior hippocampus during the associative 
encoding of stimuli that are successfully remembered with confidence compared to those 
that are not remembered. However, this pattern was absent in the MDD group, thus 
supporting the hypothesis that the normal modulation of right hippocampal activation by 
encoding strength is dysregulated in MDD. An additional analysis showed that this 
dysfunction was specific to the hippocampus and that a double dissociation between 
groups in the hippocampus and intraparietal sulcus suggest that compensatory 
mechanisms may exist. These findings provide a cutting edge tool linking memory 
impairments and hippocampal changes in MDD and to integrate several current threads 
of research to differentiate those factors which are able to be mediated by exercise and 
are correlated with improved neural function. 
One way that exercise may improve brain function in depression is by restoring normal 
hypothalamic-pituitary-adrenal (HPA) axis and immune functioning by reducing cortisol 
and pro-inflammatory cytokines levels and their toxic effects on the hippocampus in 
addition to increasing neurotrophic growth factors known to enhance neural plasticity, 
and new cell formation (neurogenesis). However the relationship between new cell 
growth, increased hippocampal volume and more efficient functional activity in the 
hippocampus has only been presumed thus far.  
With the ability to demonstrate improved hippocampal activation concomitant with 
improved memory, it is possible to determine which of the biochemical markers 
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including cortisol, inflammatory cytokines and growth factors relate to changes in 
hippocampal function. This work has the potential to provide a tool to improve exercise 
prescription, to predict exercise responders and guide development of a synergistic 
treatment approach.   
 
 




1.2 Experimental objectives and hypotheses 
1.2.1 Original Objectives 
The objectives of the proposed study are to investigate the effect of a moderate-intensity 
structured, supervised 12 week exercise program combined with a mental health day 
treatment (MHDT) program, as compared to the MHDT on its own, and exercise in a 
non-depressed group.  The outcome measures will include: Intensity of depressive 
symptoms, sleep quality, overall cognitive function, plasma IL-1β, IL-6, IFN-γ, TNF-α 
and IL-10, VEGF, BDNF and IGF, salivary cortisol, performance on an associative 
memory task and concomitant fMRI hippocampal activation. A non-depressed exercise 
group will be included to determine if the effects of exercise on the outcome measures are 
generic. All outcome measures will be assessed at baseline and 12 weeks. 
The specific objectives of this research are: 
a) To determine whether depressed individuals who perform moderate exercise 
perform better on cognitive memory tasks and demonstrate a return towards 
the profile of hippocampal activation found in non-depressed individuals: 
Hippocampal activation will be assessed using functional magnetic resonance 
imaging (fMRI) and measuring activation in the hippocampus during the 
encoding phase of a cognitive memory task.  
b) To determine whether the depressed exercise group demonstrates lower 
levels of cortisol, IL-1β, IL-6, IFN-γ,TNF-αand higher levels of IL-10, 
DHEA,VEGF, BDNF and IGF after 12 weeks compared to their own 
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baseline and to any changes in the control group, and the baseline levels in 
the non-depressed group: Participant will be sampled mid-week at waking and 
30 minutes post-awakening samples for saliva which will be brought to the 
investigators when they present for their fMRI scan. Both waking cortisol and the 
awakening response (waking – 30 minutes post awakening) will be assayed along 
with growth factors and cytokines which will be measured from plasma and 
assayed using ELISA test kits for all three groups.  
c) To investigate the relationship between changes in biochemical markers and 
changes in hippocampal function with exercise: Regression analysis will be 
used to determine whether there is any relationship between biochemical markers 
and hippocampal function. 
d) Determine whether there is relationship between improved fitness and 
improved hippocampal function: Aerobic fitness will be measured at 0 and 12 
weeks using submaximal tests of oxygen uptake (V02 max). Improvement in fitness 
will be compared to improvement in memory and hippocampal activation to 
determine if there is any correlation between the two for both exercise groups. 
 
1.2.2 Original Hypotheses 
The overall goal of this research is to investigate whether a structured, supervised 12 
week exercise program can promote changes in hippocampal function in depressed 
individuals and whether this is associated with improvements in depression, memory and 
the status of biochemical markers known to be altered in MDD. This study will be 
comparing depressed individuals who perform moderate exercise for 12 weeks in 
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addition to attending an outpatient day program to a control group who attend the day 
program only. This study will also have a matched non-depressed exercise group to 
provide normative data for comparison and to determine whether exercise also improves 
hippocampal activation and biomarker status in non-depressed individuals. 
It is hypothesized that: 
a) Improved cardiovascular fitness as measured by change in maximal oxygen 
consumption (VO2max) will be correlated with decreased cortisol levels in both 
exercise groups. 
b) Participants who receive exercise in addition to the MHDTP will show greater 
improvements in depression and hippocampal function as well as lower levels of 
cortisol than those in the MHDT only group. 
c) Performance on cognitive memory tasks with concomitant hippocampal activation 
(assessed using fMRI) will be positively correlated with improvements in 
depression scores following the 12 week exercise intervention. 
d) Changes in cortisol, IL-1β, IL-6, IFN-γ,TNF-α will be negatively correlated and 
changes in IL-10, VEGF, BDNF and IGF will be positively correlated with 
changes in hippocampal function following the 12 week exercise intervention. 
1.3 Revised Thesis objectives 
As the planning for the study began in collaboration with our partners at the Lakeridge 
MHDT (LMHDT) program it became clear that there were a large number of preliminary 
steps that would need to be completed prior to the initiation of the original aims. 
These preliminary steps included:  
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1. Completion of an in depth literature review to ensure the most relevant 
biomarkers relating to both exercise and depression would be assayed and the 
most up to date evidence based protocols for exercise and depression are utilized. 
2. Applying for grant funding to cover the costs of the fMRI scans and biomarker 
assays. 
3. Obtaining Ethical approval from three different Ethics committees (Lakeridge 
Health where patients will be sampled, UOIT and Rotman Baycrest where the 
fMRI scans would take place). 
4. Validating and piloting the planned fMRI protocol previously piloted in New 
Zealand on a 1.5 Tesla General Electric MRI scanner at the 3.0 Tesla Siemans 
MRI scanner at the Rotman Baycrest hospital. 
5. Developing a recruitment protocol from the LMHDT program to minimize the 
number of steps required for staff and potential participants. 
6. Developing protocols for blood collection, storage and biomarker assays. 
7. Preliminary testing of the baseline samples of the initial recruits to determine the 
sensitivity of the assays. 
8. Development of an organizational plan to match exercise supervisors to 
participants as each participant will be performing three one hour exercise 
sessions per week. 
Additionally, because it is clear that in order to differentiate the effects of exercise 
specific to depression from the general effects of exercise it is important to include a non-
depressed exercise group in the final study which would have been beyond the timeframe 
of a Masters‟ thesis. Therefore it was decided that that this Masters‟ thesis would become 
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a feasibility study for the larger study with the aims of completing the preliminary steps 
described above, writing an in depth methods chapter to be used in the larger study, and 
summarizing and discussing the results of the feasibility study and any implications that 
this would have for the larger study. 
1.4 Significance of the study 
The effects of depression are far-reaching, having become one of the leading contributors 
to the global burden of disease (WHO, 2008). Depression affects 1 in 20 Canadians 
(Canada 2006) with an economic burden, estimated at over 14 billion dollars annually in 
2001 (Stephens and Joubert 2001). The poor remission rates of existing antidepressant 
therapies as well as the social stigma associated with seeking medical help leaves many 
individuals undertreated (Shelton 2006). With a recent meta-analysis suggesting that 
there are minimal benefits of medication vs placebo for mild to moderate depression 
(Fournier et al. 2010), the role of non-pharmacologic treatment for depression becomes 
increasingly important. Exercise is a therapeutic intervention with proven benefits in the 
treatment of depression, but there is minimal research on its mechanism of action. 
Therefore it is fundamental to understand why and how exercise works, in order to better 
focus the exercise prescription and identify those most likely to benefit from exercise in 
place of, or in addition to, other therapies.   
It is well established that impaired episodic memory and reduced hippocampal volume is 
associated with depression, however there is controversy about the meaning and 
mechanism of these findings.  Previous pilot data suggest that hippocampal fMRI can 
distinguish between depressed and non-depressed individuals and may prove to be 
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sensitive marker of the effect of an intervention on neural function. A potential candidate 
mechanism for hippocampal and memory changes are the elevated cortisol and pro-
inflammatory cytokine levels and decreased growth factor levels observed in depressed 
individuals. This planned study will significantly advance knowledge as it is the first to 
use fMRI to measure changes in hippocampal activation following an exercise 
intervention in people with depression. By correlating changes in hippocampal activation 
with changes in cortisol, pro-inflammatory cytokines and growth factors it is possible to 
determine which of the biochemical markers is most predictive of improved neural 
function. This study will also differentiate which markers change in MHDT plus exercise 
vs MHDT alone as well as measuring whether these same markers change with exercise 
in a non-depressed group. This will create a much more solid rationale for combined 
approaches in the future. In the future it may be possible to use a person‟s “biochemical 
signature” to determine the combination of exercise, pharmacotherapy and/or 
psychological interventions are needed for synergistic effects and optimize treatment 
outcomes for an individual. This work has the potential to provide a tool to improve 
exercise prescription, to predict exercise responders and to guide development of 
synergistic treatment approaches to optimize depression outcomes for Canadians. 
1.5 Limitations 
Study design 
The proposed research will utilize a cohort control design.  Participants will be recruited 
in blocks.  Depressed Group 1 will undertake a 12 week structured, supervised exercise 
program in addition to the MHDT and they will be recruited in the first year of the study.  
Group 2 from the MHDT will be recruited in the second year so that they can be matched 
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by age, gender, pharmacotherapy and baseline fitness level to the exercise group using 
the same inclusion criteria. The reason for running the study as a cohort control rather 
than a randomized controlled trial is that the LMHDT is a group program and it might 
affect group cohesion if some participants were offered the exercise program and others 
were not.  This way everyone in the first cohort who meets the inclusion criteria will be 
given the opportunity to have the exercise program, and this will not interfere with the 
program in the way that it is currently run.  It also allows to age and gender match the 
control group in the non-exercising LMHDT cohort. 
Testing and instrumentation 
Cortisol secretion is associated with several variables such as life stressors. Saliva 
sampling at baseline and 12 weeks took place midweek on a Wednesday, due to the 
significant cortisol secretion differences on week days, versus weekends (Kunz-Ebrecht 
et al. 2004).  
Although indirect submaximal cardiorespiratory fitness tests estimating VO2max are less 
accurate than direct maximal measurements, they are more appropriate test to use when 
evaluating sedentary populations. The validity of VO2max tests can be questioned with 
variables such as motivation, however workload and durations for the Astrand-Rhyming 
cycle ergometer protocol are determined by fixed guidelines and do not allow for 
subjectivity. Additionally, provide an accurate estimation of VO2max once adjusted to the 




To prevent errors associated with self-sampling, participants will be provided with clearly 
written instructions in conjunction with a verbal explanation, at baseline and at 12 weeks. 
If a participant forgets to sample or a sampling error occurs, an alternative midweek day 
(Thursday) will be used to repeat sampling. 
To ensure that exercise attendance between-group differences could be accounted for, 
individual records were kept of session attendance so that attendance rate could be 
calculated. To remain eligible for the study, a minimum of 75% attendance is required, 
which translates to a minimum of 27 sessions out of the total 36 allotted. 
 
Controlling for the effects from social contact 
It is important to differentiate the benefits of group exercise which are specific to exercise 
as opposed to the psychosocial benefits due to the social interaction that occurs within the 
group.  A meta-analysis of 14 randomised controlled trials in this area, while finding a 
positive overall effect for exercise, identified a lack of randomisation concealment, 
blinding and intention to treat analysis in the research to date (Lawlor and Hopker 2001).  
A point raised is that positive social interactions occurring during exercise may be more 
important to the treatment effect than exercise per se, and most research is lacking the 
inclusion of contact only groups to control for the psychosocial benefits of exercise, an 
issue will be addressed as the LMHDT program provides an ideal solution to this. 
 
Chapter 2 Literature Review 
 
Lack of activity destroys the good condition of every human being, while 
movement and methodical physical exercise save it and preserve 




Major depressive disorder (MDD) is a global public-health problem and is among the most 
prevalent and burdensome of all psychiatric disorders. In Canada, it is estimated that 1 in 20 
Canadians are affected by depression and its economic burden is estimated at over 14 billion 
dollars annually (Stephens and Joubert 2001). Depression is the fourth leading cause of disease 
burden globally and is projected to be the second leading cause by the year of 2030 (WHO, 
2004). It has been estimated that 12% of men and 25% of women will experience a clinically 
significant depressive episode at least once in their lives (Shelton 2006; Gadalla 2009). 
Depression is also a severely undertreated and under recognized disorder in the primary care 
setting (Diverty and Beaudet 1997; Insel and Charney 2003; Patten and Beck 2004). The 
majority of individuals with mental illness do not consult health professionals (Insel and Charney 
2003; Gadalla 2009) and it is estimated that only 56% of depressed Canadians seek medical help. 
Of those patients who seek medical help and receive treatment with antidepressant drug therapy, 
only half achieve full remission of symptoms (i.e. absence of symptoms and return to normal 
functioning) (Fava and Ruini 2002). It seems that many patients feel the stigma of seeking
 
treatment is greater than the stigma of living with the disorder (Mojtabai and Olfson 2006). The 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
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TR) defines a depressive episode as a period greater than 2 weeks that is characterized by five or 
more symptoms ranging from depressed mood, anhedonia, feelings of worthlessness or guilt, 
suicidal ideation, changes in body weight or appetite, sleep disturbance, lack of energy, 
psychomotor agitation or retardation, decreased ability to think or concentrate (APA and DSM-
IV 2000). These symptoms are often associated with higher suicide rates and higher mortality 
rates (Kalia, 2005; Wulsin, Vaillant, & Wells, 1999). There is also strong evidence implicating 
depression in the later development of other medical illnesses such as increased abdominal fat, 
decreased bone density, hypertension, peptic ulcers and diabetes (Brown, Varghese, & McEwen, 
2004). Therefore, the need for non-pharmacologic treatments for depression is becoming 
increasingly important. 
2.2.1 Depression and memory 
Of the wide array of cognitive deficits associated with depression, memory impairment is the 
most frequently reported (Airaksinen et al. 2004). However, research in this area has presented 
ambiguous findings in terms of the type, severity and specificity of memory deficits.  One 
finding that has consistently been replicated is that of impaired episodic memory (memory for a 
specific past experience in one‟s life) with a sparing of semantic memory (present knowledge of 
universal truths such as “the sky is blue”), and other facets of memory such as short-term 
memory (Ilsley et al. 1995; Tulving and Markowitsch 1998; Sweeney et al. 2000).  However, 
some studies have found equivalence between depressed and control individuals for both 
semantic and episodic memory (Danion et al. 1995).  These conflicting findings may be due 
somewhat to differences in the sampling populations, and methodological weaknesses.  A meta-
analysis of 147 studies examining memory dysfunction in depression (Burt et al. 1995) found a 
significant, stable association between depression and memory impairment.  A more recent meta-
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analysis of 22 studies supports the relationship between depression and memory impairment, and 
furthermore reveals that depression has the greatest effect on episodic memory as compared to 
semantic and short-term memory (Zakzanis et al. 1998).  Research identifying the stage of the 
memory deficit, in encoding or retrieval, has been equivocal (Ilsley et al. 1995; Airaksinen et al. 
2004).  A meta-analysis of studies on depression and memory suggests that both encoding and 
retrieval processes are impaired somewhat in depression (Zakzanis et al. 1998). More recent, 
behavioural and neuroimaging studies have found that both the encoding and retrieval processes 
in memory are impaired in depression (Zakzanis et al. 1998; Airaksinen et al. 2004; Behnken et 
al. 2010; Fairhall et al. 2010; Milne et al. 2012). Although the neural underpinnings of impaired 
memory in MDD are not completely understood, the majority of evidence implicates abnormal 
activity in the hippocampal region critical for normal memory formation (Heckers et al. 2002; 
Sperling et al. 2003). 
 
2.2 The role of the hippocampus 
The role of the hippocampus in the formation of memories has long been recognized. The 
hippocampus is located in the medial temporal lobe and is critical for learning and the formation 
of stable declarative memory in humans. However, the exact function of the hippocampus in 
forming successful memories remains unknown (Scoville and Milner 2000; Kim et al. 2006). 
The laminae that comprise the hippocampal complex include the dentate gyrus (DG) and 
hippocampal proper, four regions of the cornu Ammonis (CA) termed CA1–CA4 which are 
based on pyramidal neuron morphology and sensitivity to anoxia (Sperling et al. 2003; Campbell 
and MacQueen 2004; Duvernoy 2005). The critical functions of the hippocampus were first 
27 
 
discovered over 50 years ago when severe amnesia and the inability to form new memories 
occurred in a patient following removal of this brain region (Scoville and Milner 2000).  
At the time of memory formation a connection must be made between the to-be-remembered 
stimulus and its context. It is the process of encoding that forms new associations between 
previously unrelated items of information and the ability to retain relational information across 
time that is considered the heart of declarative memory and the function of the hippocampal 
region (Zola et al. 2000; Sperling et al. 2003). Although the exact function of the hippocampus in 
creating successful memories is not yet fully understood, converging results from animal models 
of amnesia (Zola et al. 2000) and neuroimaging studies in humans have implicate the 
hippocampus in the process of encoding episodic memories (Köhler et al. 2000; Heckers et al. 
2002; Sperling et al. 2003). It has been assumed that long-term potentiation (LTP), a form of 
synaptic plasticity within the hippocampus, contributes to the acquisition and retention of 
memories although the exact mechanism remains unknown (Bliss and Collingridge 1993; 
Lamprecht and LeDoux 2004; Leuner et al. 2006; Fairhall et al. 2010).  
2.3.1 Hippocampus and depression 
Brain imaging studies demonstrate that psychiatric disorders such as MDD are associated with 
structural alterations such as reduced brain volume to structures that control mood and contribute 
to stress related psychiatric illnesses  (Pittenger and Duman 2007).  Combining evidence from 
animal models and post-mortem studies investigating brain tissue from depressed subjects 
further detail alterations at the cellular level, such as atrophy of dendrite processes and reduced 
neurons and glial elements (Pittenger and Duman 2007; Krishnan and Nestler 2008). However 
the specific mechanisms underlying these structural changes have not been determined (Banasr 
et al. 2011).  
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The hippocampus is particularly vulnerable to structural, functional, and neurogenic change in 
response to stress and stress-related diseases, such as depression. (Conrad 2008). To date, MRI 
studies have revealed compelling evidence that the hippocampus undergoes selective volume 
reduction in stress-related neuropsychiatric disorders such as schizophrenia and MDD (Sheline et 
al. 1996; Duman et al. 1999; Bremner et al. 2000; Czéh et al. 2001; Brown et al. 2004; Videbech 
and Ravnkilde 2004; Hickie et al. 2005; McKinnon et al. 2009; Pajonk et al. 2010).   Likewise, 
several meta analyses confirm that individuals with MDD have hippocampal volumes that are 
approximately 5-8% smaller than healthy controls (Videbech and Ravnkilde 2004; McKinnon et 
al. 2009). Importantly, hippocampal volume is negatively correlated with depression duration 
and morphological changes in the hippocampus are not evident in patients with a first episode of 
depression, suggesting cumulative damage to this area. (MacQueen et al. 2003). This work has 
recently been extended to indicate that duration of illness plays an important role as a predictor 
in hippocampal volume reduction if left untreated by antidepressant drug therapy since 
medication status may also play a central role in modulating hippocampus volume in MDD 
(McKinnon et al. 2009).  Hence, treatment early in disease progression may minimize the 
volumetric reductions that are associated with multiple episodes of depression. Hippocampus 
volumes are also associated with clinical outcome (MacQueen et al. 2008). Recently, MacQueen 
et al. (2008) examined hippocampal volumes in 63 depressed participants who had baseline MRI 
scans and then completed eight weeks of first-line pharmaceutical treatment. Researchers 
compared the hippocampal volumes between patients who met the criteria for clinical remission 
to those who did not meet the criteria for remission. Overall, patients who entered remission had 
larger hippocampal volumes than those who did not enter remission.  
29 
 
Reduced hippocampal volume is also associated with several other neuropsychiatric conditions, 
such as schizophrenia, dementia and posttraumatic stress disorder (MacQueen 2009; Pajonk et al. 
2010) . It still has not been determined whether the pathological mechanisms that result in 
reduced hippocampal volumes in patients with MDD, psychosis or dementia are unique for each 
condition or involve the same pathophysiological processes (MacQueen 2009). For instance, it 
has been difficult to determine whether there are reliable differences between individuals with 
bipolar disorder and healthy controls due to the treatment effects of lithium, comorbidity, course 
of illness and variability in subtypes of patients which may partly explain the mixed finding 
reported (MacQueen 2009). 
2.3.2 Hippocampus, depression and memory 
Memory impairments often accompany depression and are considered to be a direct result from 
structural changes in the hippocampus (Hickie et al. 2005). Hippocampal recruitment is linked 
with greater hippocampal activation as indicated by regional cerebral blood flow within the 
hippocampus (Heckers et al. 2002). In healthy individuals, fMRI revealed that there is an 
expected pattern of increased activation in the anterior hippocampus during the encoding of 
stimuli that are subsequently remembered with confidence compared to items that are not 
remembered. However, this hippocampal activation pattern is absent in depressed individuals 
suggesting a dysregulation of hippocampal function (Fairhall et al. 2010). Similarly, abnormal 
hippocampal activation was found during the memory retrieval process in depressed individuals 
(Milne et al. 2012). Given that most studies investigating the hippocampus in depression use 
volumetric imaging analysis there is limited literature regarding hippocampal function. 
Therefore, it is still unclear how or whether structural abnormalities of the hippocampus turn into 
functional abnormalities. A combination of functional and structural imaging techniques may be 
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helpful in understanding whether structural brain abnormalities translate into function 
abnormalities as well as the underlying neural basis of cognitive processes such as memory.  
2.4 Neurogenesis 
The hippocampus is a highly reactive brain structure that exhibits rapid plasticity at the 
molecular, cellular, structural and functional levels in response to a specific stimuli (DeCarolis 
and Eisch 2010). One specific feature of hippocampal plasticity noteworthy is the ability of the 
DG in the hippocampus to generate new neurons throughout life (Gould et al. 1999; Leuner et al. 
2006). In healthy brains, neurogenesis occurs mainly in two distinct areas: the subventricular 
zone, which generates new neurons in the olfactory bulb; and the subgranular zone, which 
generates new neurons in the DG of the hippocampus (Ming and Song 2005).  
Rodent studies are among the first to demonstrate the ability of neurogenesis in specific areas in 
the brain (Gould et al. 1999; van Praag et al. 1999; Deng et al. 2010). For instance, 
environmental enrichment such as larger living space, physical exercise and social interaction 
with other rodents helped to stimulate cell proliferation in the adult hippocampus as well as 
significantly increase survival time for newly generated hippocampal neurons (van Praag et al. 
1999).  Behavioural studies in rodents in which neurogenesis has been experimentally 
interrupted support the idea that the newly generated cells play a critical role in some forms of 
hippocampus-dependent learning (Winocur et al. 2006). 
Neurogenesis can also be regulated by several factors associated with an organism‟s behavioural 
states.  For instance, learning of hippocampal-dependent tasks such as maze-learning not only 
increased the number of adult-generated hippocampal granule cells (Gould et al. 1999) but also 
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increased network activity while also improving cognition (Deng et al. 2010). However, whether 
increases neurogenesis is responsible for cognitive improvements remains to be investigated. 
In the rodent hippocampus, it has been well established that exposure to chronic stress alters the 
number and morphology of neurons; however, very little is known about the likely changes that 
occur in the hippocampal vasculature. Importantly, stress-induced reductions in hippocampal 
neurogenesis occurs mainly near capillaries suggesting that decreased blood flow and capillary 
density in the hippocampus results in the onset of depression (Heine et al. 2005; Kiuchi et al. 
2012). Furthermore, the local microvasculature of hippocampus in chronically stressed mice 
show decreased capillary density in the DG (Czéh et al. 2010). Together these findings suggest 
that the development and improvement of depressive symptoms may be closely associated to 
alterations in hippocampal neurogenesis and angiogenesis (Heine et al. 2005; Kiuchi et al. 2012). 
Neurogenesis in humans is affected by a variety neurological disorders and mental illnesses, such 
as epilepsy, Alzheimer‟s disease, Parkinson‟s disease, cerebral ischemia, schizophrenia and 
depression (Zhao et al. 2008; Pajonk et al. 2010). In depression, researchers suggest that 
hippocampal atrophy is, in part, a result of suppressed neurogenesis (Sapolsky 2000; McEwen 
2005). While antidepressant pharmaceutical agents have been found to promote hippocampal 
neurogenesis and improve depressive symptom (McEwen 2005; Sahay and Hen 2007) the 
mechanism of action is unknown. However increased hippocampal neurogenesis is tightly 
correlated with other variables presumed to promote hippocampal health, such as angiogenesis, 
blood flow, growth factor production and pro-inflammatory cytokine reduction (Pereira et al. 
2007). Hippocampal neurogenesis has been proposed as a target mechanism for the amelioration 
and prevention of mental illness (DeCarolis and Eisch 2010).  
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Together, these findings implicate the hippocampus in the aetiological, rather than purely 
symptomatic, role in MDD (Fairhall et al. 2010). However, the relationship between these 
findings of macro and microscopic changes and evidence for alterations in hippocampal function 
has remained elusive (Werner et al. 2009). Therefore, a better understanding of how newly 
generated neurons function and integrate into existing hippocampal circuitry is needed 
(DeCarolis and Eisch 2010). Assessing hippocampal function by neuroimaging techniques such 
as fMRI during a behavioural task will help fill this gap in research. 
2. 5 The stress response  
The stress response is a multifaceted biochemical cascade of diverse chemicals that can affect 
brain structures, physiological processes and memory (Kim and Diamond 2002).  The secretion 
of glucocorticoids hormones, cortisol (in humans) or corticosterone (in rodents) is the most 
important endocrine component of the response to stress and the one that is most necessary for 
successful adaptation (Checkley 1996). Brief episodes of stress are beneficial for an organism as 
it increases focus, alertness and enhances memory and learning  in order to cope with threatening 
situations (McEwen and Sapolsky 1995; Krugers and Hoogenraad 2009). Although the stress 
response is an essential survival mechanism, the inability to respond appropriately to intense or 
prolonged periods of stress can have deleterious physiological and psychological consequences 
(Kim et al. 2006). For instance, elevated cortisol has been associated with increased risk of 
several diseases such as cardiovascular disease, Type 2 diabetes,  reduced immune functioning 




2.5.1  Stress and the HPA axis 
A characteristic feature of MDD that has been found over the past several years is the 
disturbance in the HPA functionality (Herbert et al. 2006). Glucocorticoids have been associated 
with the regulation of neuronal survival, neurogenesis, the acquisition of new memories, the 
emotional appraisal of events and the immune response to stress (Herbert et al., 2006). 
Consequently, the role of glucocorticoids in both the stress response and brain functioning could 
partly elucidate the HPA abnormalities associated with psychiatric disorders such as depression. 
HPA axis activation results in the increased secretion of adrenal glucocorticoids such as cortisol. 
Stress is perceived by the brain cortex and the amygdala and is transmitted to the hypothalamus 
to release corticotropin-releasing hormone (CRH). CRH then stimulates the anterior pituitary 
gland to secrete corticotropin into the bloodstream. Corticotropin then stimulates the adrenal 
cortexes to secrete the glucocorticoid hormone cortisol. Cortisol sequentially induces feedback 
inhibition in the hypothalamus and the pituitary, suppressing the production of CRH and 
corticotropin, respectively (Figure 2.5) (Belmaker and Agam 2008). Under normal conditions, 
increased circulating cortisol inhibits HPA axis activity via a negative feedback mechanism by 
binding to glucocorticoid receptors at the levels of the hypothalamus and the pituitary (Blume et 
al. 2011). However, in chronic stress and psychiatric disorders such as depression, it has been 




Figure 2.5: The Hypothalamic–Pituitary–Cortisol System in Depression. From: New England Journal of 
Medicine, Belmaker, R. and Agam, G.,  Major Depressive Disorder, 358, p 61. Copyright © (2008) 
Massachusetts Medical Society. Reprinted with permission. 
2.6 Cortisol 
Cortisol is a steroid hormone that is produced by the adrenal cortex (Saladin 2001). Cortisol is 
associated with the response and adaptation to stress and is regulated through a HPA axis 
negative feedback inhibition by corticotropin (Saladin 2001). Cortisol concentrations can be 
measured in blood, urine and saliva (Saladin 2001). In blood, approximately 20% of cortisol is 
unbound and biologically active while the remaining 80% of cortisol is bound to cortisol-binding 
globulin (le Roux et al. 2003). Unbound cortisol enters the saliva via intracellular mechanisms 
where the majority remains unbound (Vining et al. 1983). As a result, salivary measures of 
cortisol accurately represent free cortisol and are more sensitive to subtle changes when 
compared to measuring cortisol in plasma or serum (Guechot et al. 1982; Vining et al. 1983; 
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Gozansky et al. 2005). Cortisol production has a distinct circadian rhythm with levels peaking in 
the early morning and dropping to the lowest concentration at night (Stone et al. 2001). 
Typically, a secretory burst in cortisol, referred to as the cortisol awakening response (CAR), 
occurs 30 minutes post awakening in which free cortisol concentration increases by 
approximately 50-75% (Schmidt-Reinwald et al. 1999; Wust et al. 2000b; Wilhelm et al. 2007). 
The CAR is considered a reliable biomarker of HPA axis activity (Pruessner et al. 1999; Wust et 
al. 2000a) and can be altered with psychological disorders such as depression (Stetler and Miller 
2005; Adam et al. 2006; Foley 2006; Huber et al. 2006). Similarly, chronic elevations of cortisol 
are associated with a wide array of health consequences such as cardiovascular disease, bone 
loss, immune dysfunction and metabolic syndrome (Brunner et al. 2002; Lundberg 2005; 
Reynolds et al. 2005). . 
Cortisol secretion is a highly variable function that is associated with variables such as sex, 
socioeconomic status, sleep disturbance and increased perceived stress particularly on workdays 
compared to weekends (van Eck et al. 1996; Wust et al. 2000b; Backhaus et al. 2004; Kunz-
Ebrecht et al. 2004). Table 2.6 illustrates the wide range of values that represent cortisol 
concentrations in normal healthy individuals which will be used as normative data in this study 
(Clow et al. 2004). 
Table 2.6 Cortisol levels and CAR in healthy individuals (Clow et al. 2004) 
 Mean  SD Range 
0 min post-waking (nmol/L) 11.6 4.6 4.7 – 18.5 
30 min post-waking (nmol/L) 20 5.9 8.6 - 28 
Percentage increase 0-30 min (%) 91.4 42.4 50 - 156 




2.6.1 Cortisol, stress and depression  
Chronic stress is known to be a strong causal factor in the onset of depression (Kendler et al. 
1999). Too much stress and increased cortisol is a major risk factor for mental illness such as 
depression and other psychotic disorders (Brown et al. 2004; Phillips et al. 2006). It has been 
well established that inventories of stressful events predict subsequent depression (Kessler 1997) 
and stressful events are often associated with the onset of MDD (Kendler et al. 2000). The 
glucocorticoid cortisol is a major mediator of the physiological stress response. Excess cortisol 
secretion is reported to be one of the risk factors for subsequent depression (Herbert et al. 2006). 
Not surprisingly, elevated cortisol is a hallmark finding in patients with MDD (Davis et al. 1987; 
Newcomer et al. 1999; Sapolsky 2000; Young et al. 2001; Brown et al. 2004; Krishnan and 
Nestler 2008).  
HPA axis dysregulation is commonly implicated in the course of depressive illness. The 
hypothalamic-pituitary-cortisol hypothesis of depression (see Figure 2.6) postulates that 
abnormalities in the cortisol response to stress may underlie depression (Belmaker and Agam 
2008). The hippocampus participates in the termination of the stress response through the 
glucocorticoid-mediated negative feedback that inhibits the HPA axis (Kim and Diamond 2002; 
Sapolsky et al. 2002). In depression, the negative feedback mechanism is impaired resulting in 
an increased activity of the HPA axis and elevated cortisol secretion. (Belmaker and Agam 2008; 
Hinkelmann et al. 2009).  It is still disputed whether these phenomena are a consequence of 
MDD or whether they represent a vulnerability marker existing before the illness onset (Dedovic 
et al. 2010). However, it has been shown that normalization of circulating cortisol levels with 
antiglucocorticoid therapy alleviates depressive symptomatology in both patients with Cushing‟s 
disease and hypercortisolemic depressed patients and has been associated with successful clinical 
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treatment outcomes (Murphy and Beverley 1997; Reus et al. 1997; Herbert et al. 2006).  
Furthermore, the diurnal rhythm of cortisol secretion is also blunted in depression; pulses tend to 
be longer and more frequent, with levels remaining consistently high over the day (Stokes 1995).  
However findings have been inconsistent across studies (Chida and Steptoe 2009). A recent 
meta-analysis found that the magnitude of the CAR is related to a number of psychosocial 
factors. Specifically, researchers found that the CAR was positively associated with job stress 
and general life stress and was negatively associated with fatigue, burnout, and exhaustion 
(Chida and Steptoe 2009). 
2.6.2 Cortisol and memory 
Stress-induced elevated cortisol levels have well-known effects on cognition. Increasing 
evidence has found that exposures to stress and/or stress hormones impair hippocampal-
dependent forms of memory in both humans and animals. Both chronic and acute elevations in 
cortisol due to either prolonged stress or experimental injections have consistently been linked 
with cognitive deficits such as effortful processing and episodic memory impairment (Rubinow 
et al. 1984; Bemelmans et al. 1996; Lupien et al. 1998; Newcomer et al. 1999; Dominique et al. 
2003; Sauro et al. 2003; Buss et al. 2004; Herbert et al. 2006; Hinkelmann et al. 2009). This 
pattern of increased cortisol and memory deficits has been replicated in Lupien‟s work in 
hypercortisolemic aged populations (Lupien et al. 1998), and in those with Cushing‟s Disease, a 
state characterised by hypercortisolemia (Starkman et al. 2001).  Chronically high levels of 
cortisol have been associated with memory deficits in those with depression, and successful 
treatment has been associated with decreases in cortisol secretion and subsequent improvement 
in episodic memory function (Vythilingam et al. 2004). Also, cortisol is known to reduce 
hippocampal long-term potentiation (LTP), a form of synaptic plasticity essential for 
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hippocampal-dependent memory formation (McEwen and Sapolsky 1995; Joels 2008; 
Hinkelmann et al. 2009; Krugers and Hoogenraad 2009).  
2.6.3 Cortisol and the hippocampus 
The biological mechanisms leading to hippocampal volume reduction in depressive disorders are 
currently unclear. One possible mechanism of injury to the hippocampus is corticosteroid 
exposure (Brown et al. 1999). Chronic stress, hyperactivation of the HPA axis and elevated 
cortisol levels have all been suggested to play a role in the down-regulation of neurogenesis, the 
volumetric changes of the hippocampus and the deficits in functional capacity of the 
hippocampus (Starkman et al. 1992; Sheline et al. 1996; Brown et al. 1999; Duman et al. 1999; 
McEwen 2000; Sapolsky 2000; Herbert et al. 2006; Mondelli et al. 2010).  
The hippocampus also plays a role in terminating the HPA stress response, however, injury to 
the hippocampus impairs this negative feedback mechanism resulting in a more prolonged HPA 
response to psychological stressors (Brown et al. 1999; McEwen 2007). The “glucocorticoid 
cascade hypothesis” (Sapolsky et al. 2002) suggests that there is an association between 
cumulative exposure to high cortisol levels and hippocampal atrophy. Increases in cortisol levels 
produce hippocampal damage resulting in even greater increases in cortisol secretion due to 
impaired feedback mechanisms to suppress cortisol release. The “neurotoxicity hypothesis” 
(Gilbertson et al. 2002), suggests that chronic secretion of elevated glucocorticoids results in the 
neurotoxic effects on the hippocampus, such as disruptions in glucose metabolism, dendrite 
branching and neurogenesis which ultimately leads to hippocampal atrophy (Lupien et al. 2009). 
The hippocampus is one of the main glucocorticoid target sites in the brain, with copious 
amounts of corticosteroid receptors (Sapolsky 2000; McEwen 2005; Hinkelmann et al. 2009) 
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making it extremely sensitive to increased glucocorticoid levels. Stress hormones such as cortisol 
modulate function within the hippocampus by plasticity (adaptation, changing or remodelling the 
structure of neurons) to possibly avoid over-exposure to elevated glucocorticoid levels (Duman 
et al. 1999; McEwen 2000; Lee et al. 2002; Campbell and MacQueen 2004; McEwen 2005; 
Conrad 2008). As a result, excessive exposure to glucocorticoids have profound effects on the 
hippocampus such as volume loss, dendritic atrophy, inhibiting neurogenesis and neuron death 
(Brown et al. 1999; Duman et al. 1999; Newcomer et al. 1999; Bremner et al. 2000; Sapolsky 
2000; Lee et al. 2002; Brown et al. 2004; McEwen 2005; Pittenger and Duman 2007; Mondelli et 
al. 2010).  
To test the hypothesis that dysregulation of the HPA axis and hippocampal volume abnormalities 
would represent vulnerability factors for depression, Dedovic et al., (2010) compared the CAR 
and hippocampal volume in healthy control subjects and individuals at risk for depression.  
Supporting their hypothesis, a dysregulated CAR and smaller hippocampal volume was observed 
in the subclinical high risk group (Dedovic et al. 2010). 
2.6.4 Cortisol and neurogenesis 
In rodents, exposure to high levels of glucocorticoids decreases neurogenesis of DG granule 
neurons in the hippocampus (Gould et al. 1998; Ekstrand et al. 2008). Therefore, it has been 
proposed that the down-regulation of neurogenesis is a potential mechanism for the observed 
decrease in hippocampal size as seen with neuroimaging of depressed individuals (MacQueen et 
al. 2003; Belmaker and Agam 2008). Likewise, the down-regulation of neurogenesis in response 
to increased levels of glucocorticoids could contribute to deficits in the functional capacity of the 
hippocampus resulting in learning and memory impairments (Kim et al. 2006).   
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Although there is a relationship between high cortisol levels and reduced hippocampal volume, 
this does not suggest that cortisol alone is the only cause but instead the underlying mechanisms 
may be associated to the activation of the stress response (Dedovic et al. 2010; Mondelli et al. 
2010). For example, glucocorticoids increase the release, as well as decrease the clearance of 
glutamate. Glutamate is the major excitatory neurotransmitter in the brain and at elevated levels 
becomes neurotoxic leading to the neuronal atrophy associated with chronic stress and 
depression (Banasr et al. 2011).  
The causal relationship between hypercortisolism and depressive symptoms such as memory 
impairment has not been established and is it likely to dissociate the effects of depression and 
hypercortisolism on memory impairment in MDD (Egeland et al. 2005). For instance, findings of 
memory deficits in other clinical groups suffering from hypercortisolism such as Cushing‟s 
disease implies a direct relationship between cortisol and memory dysfunction  that is not 
facilitated by depression (Egeland et al. 2005). Additionally, depression is only seen in 50% of 
Cushing‟s disease patients indicating that depression is secondary to hypercortisolism (Checkley 
1996).  However, conclusive evidence linking hippocampal dysfunction with elevated cortisol to 
determine whether hippocampal alterations are secondary to increased cortisol and if these 
changes are reversible for early intervention therapy levels has not yet been determined 
(Sherwood 1997). The hippocampus may be a possible candidate for mediating the effects of 
cortisol on episodic memory however there is a lack of understanding about the differences 
between rodent and human hippocampal neurogenesis.  
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2.7 Inflammation and cytokines 
Previously, the majority of research on depression, neurodegeneration and decreased 
neurogenesis investigated the effects of elevated glucocorticoids. More recently, MDD has been 
suggested to be a psychoneuroimmunological disorder, in which peripheral immune activation, 
via cytokine release, is responsible for the array of behavioural, neuroendocrine and 
neurochemical changes that occur with this disorder (Schiepers et al. 2005).  
Cytokines are proteins that are released by a variety of cells and serve as intercellular signals 
regulating immune responses. Cytokines encompass a heterogeneous group of messenger 
molecules that are produced by immunocompetent cells, such as lymphocytes and macrophages, 
to regulate immune responses (Schiepers et al. 2005). Similar to hormones of the endocrine 
system, cytokines transmit messages by interacting with receptors on cell surfaces to 
communicate throughout the body (Robles et al. 2005). Cytokines can be divided into two broad 
classes based on their effects on the immune response: pro-inflammatory (stimulating 
inflammation) and anti-inflammatory (reducing inflammation) (Robles et al. 2005; Schiepers et 
al. 2005). Pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α 
(TNF-α) and interferon (IFN), are produced by cells at the site of infection or injury to attract 
other immune cells and signal them to activate and respond. Anti-inflammatory cytokines reduce 
this immune response, inhibiting immune-cell activities, such as replication, activation, and 
synthesis of other cytokines (Robles et al. 2005).  
Since peripheral cytokines are relatively large molecules and do not freely pass through the 
blood-brain barrier (BBB) research has focussed on the pathways by which peripheral cytokine 
signals reach the brain (Raison et al. 2009). Animal research indicates that cytokines 
administered peripherally can access the brain and affect function through several pathways via: 
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vagal nerve activation, a leaky or compromised BBB, active transport across the BBB, or 
binding to cell-surface proteins on brain endothelial cells. (Dantzer et al. 2008; Miller et al. 2009; 
Loftis et al. 2010). Pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α that sub serve 
inflammation in the periphery have complex and contrasting functional roles in the CNS (Miller 
et al. 2009). Under normal physiological conditions, these cytokines are important for providing 
trophic support to neurons, enhancing neurogenesis, and contribute to cognitive functioning such 
as memory (Miller et al. 2009). However, in the milieu of excessive and/or prolonged activation, 
cytokine networks in the CNS can encourage an interconnected group of abnormalities that are 
thought to be partly responsible for the pathophysiology of depression, such as reduced 
neurotrophic support, decreased neurogenesis, increased glutamatergic activation, oxidative 
stress, induction of cell apoptosis and impaired cognitive function (Miller et al. 2009). 
Overall, cytokines have been found to access the brain and interact with nearly every 
pathophysiologic domain relevant to depression, including neuroendocrine function, 
neurotransmitter metabolism, and neural plasticity (Miller et al. 2009). There is a growing body 
of evidence that activation of pro-inflammatory cytokines and/or inhibition of anti-inflammatory 
factors cytokines have been reported to modulate CNS functions and contribute to the changes 
involved in psychiatric and neurodegenerative diseases such as depression (Song et al. 2003; 
Hayley et al. 2005; Irwin and Miller 2007; Song and Wang 2010).  
2.7.1 Cytokines and depression 
Depression is a multifaceted disorder and the pathogenesis of the disease likely involves 
alterations in several systems which interact with one another. Findings that cytokine-mediated 
inflammatory processes play a critical role in the development of depression is quite robust 
(Zunszain et al. 2011). Depression is highly prevalent among patients suffering from infectious, 
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autoimmune and neurodegenerative diseases, and this co-morbidity cannot be attributed solely to 
the psychological distress of the initial disease (Pollak and Yirmiya 2002; Rook and Lowry 
2008).  
The „„Cytokine Hypothesis of Depression‟‟ proposes that inflammation may be a causal 
mechanism in the development of depressive symptomatology (Dantzer et al. 2008; Miller et al. 
2009). Research indicates that individuals with depression and other psychiatric disorders 
express elevated immune markers (Archer et al. 2010). An experimental model for assessing the 
acute immune response to infection in humans is the administration of the endotoxin 
lipopolysaccharide (LPS) (Reichenberg et al. 2001). Both acute and chronic administration of 
cytokines (or cytokine inducers such as LPS or vaccination) can result in behavioural symptoms 
similar to those found in major depression. Likewise, data in humans are consistent with animal 
findings, acute administration of LPS to humans leads to a host of behavioural changes, 
including depressed mood, anhedonia, sleep disturbance, fatigue, and cognitive dysfunction 
(Reichenberg et al. 2001; Dantzer et al. 2008; Harrison et al. 2009; Eisenberger et al. 2010; 
Loftis et al. 2010; Haroon et al. 2011). Interestingly, the concentration of these cytokines in the 
blood correlates with the severity of depression and the administration of antidepressant 
medication normalizes the elevated pro-inflammatory cytokine levels (Miller et al. 2009; Janssen 
et al. 2010)  
The main pro-inflammatory cytokines IL-1β, IL-6, IFN-γ and TNF-α are considered to be one of 
the most reliable peripheral biomarkers in MDD (Mössner et al. 2007) as they consistently 
appear to be elevated in depressive states or in response to psychological stress (O'Brien et al. 
2004; Schiepers et al. 2005; Raison et al. 2006; Piletz et al. 2009; Dowlati et al. 2010). For 
instance, depressed patients who had attempted suicide have shown increased IL-6 in 
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cerebrospinal fluid (Lindqvist et al. 2009) and chronic administration of the inflammatory 
cytokine IFN-α induces depressive symptoms in up to 30–50% of IFN-α treated patients. 
(Musselman et al. 2001; Raison et al. 2005; Asnis and De La Garza 2006; Raison et al. 2009).  
Recent meta-analyses exclusively that examined pro-inflammatory markers determined that 
circulating peripheral C-reactive protein (CRP), TNF-α, IL-6, and IL-1β were all significantly 
elevated in association with a diagnosis of MDD (Howren et al. 2009; Dowlati et al. 2010). A 
prospective study found that an increased inflammatory state at baseline (defined as elevated 
levels of CRP and increased capacity of leukocytes to produce IL-1), predicted a later onset of 
depression in elderly individuals with no previous history of depression indicating that excess 
inflammation precedes depression (van den Biggelaar et al. 2007; McNally et al. 2008).  
The ratio of pro-inflammatory to anti-inflammatory cytokines may also be disrupted in 
depression and result in a net increase in inflammatory activity (Dhabhar et al. 2009). Decreased 
IL-10 levels, a higher IL-6/IL-10 ratio, and the lack of a counter-balancing, immunoregulatory 
increase in IL-10 in response to increased IL-6 concentrations underlie the pro-inflammatory 
physiological environment that is found to be associated with MDD. As a result, a reduction in 
IL-10 that would normally dampen pro-inflammatory cytokine actions and resolve inflammation, 
may contribute to the depressogenic, in addition to the inflammatory disease-promoting effects 
of chronic, low-level elevations in pro-inflammatory cytokines (Dhabhar et al. 2009). 
2.7.2 HPA axis and cytokines 
The human stress response has a several checks and balances built in place to ensure that various 
components do not become over or underactive (Kendall-Tackett 2009). The stress response 
system is intricately linked with pro-inflammatory signalling. In the event of severe stress and 
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disrupted glucocorticoid signals, the result may be reduced restraint on the immune system and 
the overproduction of pro-inflammatory cytokines (Raison and Miller 2003).  
For example, cortisol is normally anti-inflammatory and keeps pro-inflammatory cytokines in 
check however under severe stress cortisol can change function and potentiate the actions of IL-1 
and IL-6 rather than inhibiting them. As a result, pro-inflammatory cytokines may themselves 
disrupt cortisol signaling and negative feedback regulation of the HPA axis, further increasing 
risk for depression (Robles et al. 2005) 
Particularly, IL-1, IL-6, TNF- α and IFN- γ induce a cascade of behavioural, neuroendocrine and 
central neurotransmitter changes including direct stimulation of the HPA axis and secretion of 
cortisol (Song 2002; O'Brien et al. 2004; Hayley et al. 2005; Schiepers et al. 2005; Dantzer et al. 
2008).  Increased glucocorticoid levels found in depression are partly a result of increased 
production of pro-inflammatory cytokines, such as IL-1β and IL-6 (Maes et al. 2009). For 
example, chronic administration of IFN-α to humans led to increased cortisol levels and 
flattening of the diurnal cortisol slope which was also associated with depression and fatigue 
(Raison et al. 2008). These findings parallel the correlations between flattening of the cortisol 
curve and plasma IL-6 in patients with advanced cancer (Capuron et al. 2003; Bower et al. 2005; 
Rich et al. 2005) 
As previously mentioned, it is becoming increasingly evident that in certain disorders, such as 
depression, these inhibitory feedback loops become impaired, allowing for chronic immune 
activation and the persistence of sickness symptoms that present from this activation (Irwin and 
Miller 2007).  In depression, both cortisol and pro-inflammatory cytokine levels are elevated, 
46 
 
which also indicates a failing or dysregulation of HPA-axis feedback mechanism (Raison and 
Miller 2003; O'Brien et al. 2004; Pace et al. 2007; Leonard and Myint 2009).   
2.7.3 Cytokines, neuroplasticity and memory 
Accumulating evidence indicates that cytokines are critical to the regulation of neuronal 
plasticity and survival, and that prolonged disruption of the balance of these cytokines can lead 
to alterations in brain structures and function (Loftis et al. 2010). In clinical populations, a 
consistent finding is that hepatitis patients treated with IFN therapy often develop a wide array of 
cognitive impairments (Reichenberg et al. 2005; Lieb et al. 2006). It has been proposed that 
inflammation impacts cognitive function through effects on neurogenesis and synaptic plasticity 
(Bernardino et al. 2008; Dantzer et al. 2008; Maes et al. 2009; McAfoose and Baune 2009; 
Dantzer 2012). A possible mechanism for the negative effects of pro-inflammatory cytokines is 
their ability to modulate hippocampal neurogenesis through their activity on cytokine pathways 
and messenger systems (Dowlati et al. 2010). Specifically, elevations in pro-inflammatory 
cytokines influence neuronal functioning via cell apoptosis, oxidative stress, metabolic 
derangement, and by impairing processes of neuronal branching (Hayley et al. 2005).  
Cognitive-behavioural studies in animals have shown that inflammatory manipulations which 
substantially increase IL-1 in the hippocampus (either endogenously or exogenously) result in 
impairments of hippocampal-dependent memory consolidation, inhibit LTP and cell proliferation 
and promote cell atrophy in the DG and CA regions of the hippocampus (Vereker et al. 2000; 
Song 2002; Avital et al. 2003; Barrientos et al. 2006; Goshen et al. 2007; Hennigan et al. 2007; 
Pickering and O‟Connor 2007; Chen et al. 2008).  
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The involvement of IL-1 in hippocampal-dependent memory processes follows an inverted U-
shape pattern, such that basal levels of IL-1 are required for memory formation, and any 
deviation from this physiological range either by an excessive increase in IL-1 levels or by 
blockade of IL-1 signaling, impairs memory (Avital et al. 2003; Goshen et al. 2007). What‟s 
more, the memory impairments following central administration of IL-1 may be associated with 
hypercortisolemia, as the cognitive disturbances were reversed not only by IL-1 receptor agonist, 
but also by a glucocorticoid receptor antagonist (Song 2002).  Therefore, cortisol alone may 
provide an incomplete estimate of the effects of hypercortisolemia (Bauer et al. 2009). 
2.8 Neurotropic growth factors 
Neurotrophic growth factors such as BDNF, IGF and VEGF contribute to a variety of neural 
processes including neural development, neuronal survival, synaptic signalling and synaptic 
consolidation making them attractive candidates for the cellular mechanisms underlying both 
depression-induced changes and antidepressant responses (Allen and Dawbarn 2006; Warner-
Schmidt and Duman 2008). Stress has been found to decrease levels of VEGF and BDNF in the 
hippocampus, as well as produce neuronal atrophy and reduce neurogenesis, which may 
contribute to a depressogenic state (Duman and Monteggia 2006). Several studies that have 
assessed BDNF levels in MDD found important correlations between stress, MDD and 
neurotrophic growth factor levels. A post-mortem study of depressed patients who had 
committed suicide found reduced hippocampal BDNF (Karege et al. 2005) and several 
biochemical studies have found low BDNF levels in depressed subjects (Shimizu et al. 2003; Lee 
et al. 2007; Bocchio-Chiavetto et al. 2010) as well as a negative correlation with the depression 
severity (Shimizu et al. 2003).  
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The „„neurotrophic model‟‟ of depression (Duman and Monteggia 2006) postulates that reduced 
hippocampal BDNF activity, caused by stress or elevated glucocorticoids, impairs the ability of 
stem cells in the subgranular zone of the DG to proliferate into mature cells that remain viable 
(Duman and Monteggia 2006; Wolkowitz et al. 2010).  There is also evidence that the 
downregulation of BDNF by acute stress is mediated by the pro-inflammatory cytokine IL-1β  
(Barrientos et al. 2003). 
However, antidepressants have been shown to increase levels of VEGF, BDNF, IGF-1, restore 
neuronal atrophy, and increase neurogenesis (Warner-Schmidt and Duman 2006; Wolkowitz et 
al. 2010). BDNF has anti-inflammatory and antioxidant effects as well as attenuating 
glucocorticoid-induced neuronal death by promoting the growth of developing neurons 
(Wolkowitz et al. 2010). The suggested role of BDNF in antidepressant mechanisms is supported 
by research that hippocampal neurogenesis (in animals) and serum BDNF concentrations (in 
depressed humans) increase with antidepressant therapy (Hashimoto et al. 2004).  In rodents, 
BDNF administration to the DG of adult rats leads to increased neurogenesis of granule cells 
(Scharfman et al. 2005) in addition to having antidepressant-like effects (Shirayama et al. 2002) .  
In depressed humans, antidepressants increase BDNF levels (Shimizu et al. 2003) as well as 
improve depression scores (Brunoni et al. 2008). Research has also found that stress-induced 
decreases in neurogenesis and the expression of relevant nerve growth factors which support 
neurogenesis, can be reversed by the administration of an IL-1 receptor antagonist (Barrientos et 
al. 2003; Duman 2009). 
It has been hypothesized that the regulation of neuroplasticity is mediated by various growth 
factors (Duman et al. 2009; Paslakis et al. 2012). Similar to BDNF, IGF-I, produces 
antidepressant-like behavioural effects (Duman et al. 2009) as well as increases adult 
49 
 
hippocampal neurogenesis in the rodent brain (Trejo et al. 2001). Interestingly, researchers 
suggest that at BDNF plus IGF-I act synergistically producing a more robust effect than either 
neurotrophin alone in activating neurotrophic cascades that alter ongoing neuroplasticity 
mechanisms which promote the survival of new and existing hippocampal neurons (Cotman et 
al. 2007; Paslakis et al. 2012) . In support of this, researchers have shown that the maximal 
survival of new neurons in the rat hippocampus is achieved when both growth factors are present 
(Johnson-Farley et al. 2006).   
Astroglia also play a part in neuroplasticity through the secretion of neurotrophic factors 
(McNally et al. 2008). Reduced astroglia numbers, another feature of depression, disrupts the 
balance of anti- and pro-inflammatory mediators and further impairs the elimination process of 
excitatory amino acids. Microglia activated by increased inflammation, astroglial loss, and 
abnormal glutamate receptor activation disrupt the delicate balance of neuroprotective vs 
neurotoxic effects in the brain, possibly leading to depression (McNally et al. 2008). 
The majority of research to date found that BNDF levels increase following antidepressant 
treatment, however the results are mixed. An important research question is whether changes in 
BDNF levels are specific to certain types of antidepressant treatments or whether BDNF levels 
are associated with an overall improvement in depressive symptomatology (Brunoni et al. 2008). 
2.9 Current therapies for depression 
In order to determine whether antidepressant therapy has been successful, the desired outcome 
must be clearly defined. Response rate is defined as > 50% improvement from baseline on a 
recognized rating scale for depression such as the HADS or the BDI. Nonetheless, many patients 
with a 50% reduction in HADS score continue to experience significant residual symptoms and 
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may still meet diagnostic criteria for MDD (Shelton 2006). As a result, remission rate (i.e., 
recovery) has mostly replaced treatment response (improvement) as the standard for successful 
therapy. Therefore, patients are considered to be in remission when symptoms are absent and 
there is a full restoration with no impairments in psychosocial functioning (Shelton 2006). 
The mainstream interventions for treating MDD are pharmacological therapy, electroconvulsive 
therapy (ETC) and psychotherapy. However the effect of these treatments is far from 
satisfactory. For instance, a placebo-controlled trial compared Cognitive Behavioural Therapy 
(CBT), a form of psychotherapy, and antidepressant medication in moderately to severely 
depressed individuals who were randomly assigned to 16 weeks of CBT or pharmaceutical 
therapy or 8 weeks of pill placebo. At eight weeks, response rates were 50% in the medication 
group and 43% in the CBT group and both superior to the placebo group (25%). When 
researchers reassessed patients eight week later they found remission rates were only 46% for the 
medication group and 40% for the CBT group (DeRubeis et al. 2005).  
Generally, ECT is currently considered to be the most effective treatment for major depression 
(Shelton 2006). Approximately 60% to 80% of all depressed patients who receive a course of 
ECT respond to this treatment (Remick 2002). Although the mechanism of efficacy of ECT 
remains unclear and the use of ECT is uncommon and mainly considered a last resort treatment 
option (Remick 2002; Shelton 2006). 
The low remission rates associated with current therapies are mainly a result of poor patient 
compliance to treatment due to the wide range of side-effects accompanied by antidepressant 
medication and ECT (Remick 2002; Shelton 2006). For that reason, these trends indicate a need 
for more effective treatment options and the role of non-pharmacologic treatments for depression 
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becomes increasingly important. As well, researchers must consider strategies to address the 
needs of patients with failed initial treatments as well as target individuals who are reluctant to 
seek medical help. 
2. 10 Exercise and depression 
Due to the unsatisfactory mainstream antidepressant therapies, newer non-pharmacologic 
therapeutic options are needed for the treatment of MDD. Research has found that higher 
cardiorespiratory fitness levels and increased habitual physical activity are associated with lower 
depressive symptomatology and greater emotional well-being (Martinsen 1990; Galper et al. 
2006; Boettger et al. 2009). Additionally, lower cardiovascular fitness in adolescents is 
associated with increased risk of serious depression in adulthood (Åberg et al. 2012) and MDD 
patients who are moderately physically active are more likely to seek treatment than inactive 
MDD patients (Diverty and Beaudet 1997). Exercise alone or in combination with other 
treatment options, such as pharmacotherapy or cognitive behavioural therapy, have all been 
effective in treating depression (Blumenthal et al. 1999; Perraton et al. 2010). For this reason, the 
potential use of exercise as an alternative or complementary therapy for depression has received 
considerable attention recently.  
Both aerobic and anaerobic forms of exercise are equally effective in alleviating symptoms 
associated with depression (Doyne et al. 1987; Martinsen et al. 1989). However, a higher 
exercise dose leads to greater reductions in depression scores than a low dose (Dunn et al. 2005), 
indicative of a possible dose-response for exercise, though further replication of this work is 
needed. Overall, the general consensus from studies that report the aerobic intensity and 
frequency suggest that 60–80% of maximum heart rate, three 30-minute sessions per week, with 
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an overall duration of 8 weeks is required for a significant improvement in depressive symptoms 
(Perraton et al. 2010). It is likely that exercise-mediated amelioration of depression may be 
explained by synergistically acting psychological and physiological mechanisms (Backhaus et al. 
2004).  Physical activity reduces self-reported and clinical depressive symptoms (Koehl et al. 
2008), improves learning and memory (Ernst et al. 2006)  alters physiological function of the 
hippocampus as demonstrated by increased neurogenesis (Cotman and Berchtold 2002; Ernst et 
al. 2006; Cotman et al. 2007; Pereira et al. 2007; Koehl et al. 2008; Praag 2008; Wu et al. 2008) 
and hippocampal BDNF (Ploughman et al. 2007), reduces cortisol secretion (Nabkasorn et al. 
2006; Foley et al. 2008) and even has increased brain volume in elderly individuals (Colcombe et 
al. 2006).  Mild group jogging reduced urine cortisol and epinephrine excretions,  alleviated 
MDD, and improved cardio-respiratory fitness (Nabkasorn et al. 2006).   
Research in both animal and human subjects suggest that aerobic fitness has a strong biological 
basis in the role of maintaining and enhancing central nervous system health as well as 
substantial antidepressant effects in psychiatric patients (Martinsen et al. 1985).  In fact, the 
response rates for exercise were generally comparable to antidepressant medication (Martinsen et 
al. 1985; Blumenthal et al. 1999; Babyak et al. 2000; Blumenthal et al. 2007)  and both tend to 
be better than placebo (Blumenthal et al. 2007). An earlier study conducted by Martinsen et al. 
(1985) found that the combination of exercise with tricyclic antidepressants was not more 
effective than exercise as a monotherapy. In a similar study, the efficacy of 16 weeks of aerobic 
exercise training was comparable to standard pharmacotherapy in treating MDD. Blumenthal et 
al., (1999) randomly assigned 156 patients with MDD to 4 months of aerobic physical exercise 
alone, 4 months of antidepressant treatment (sertraline) or 4 months of combination treatment in 
the form of both medication and physical exercise. All three groups exhibited significant 
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reductions in depressive symptoms and no significant differences were observed between groups 
at 4 months, although, the onset of effect was more rapid with the drug treatment.  Remarkably, 
when researchers reassessed the patients 6 months after completion of treatment they found that 
the 10-month relapse rate was significantly lower in the exercise group (8%), when compared to 
the sertraline (38%) or the combination group (31%). Combining exercise with medication 
adding no additional gain over either treatment alone, suggesting that exercising on one‟s own 
initiative during the follow-up period was associated with a reduced probability of depression 
diagnosis at the end of that period (Babyak et al. 2000). Consistent with previous findings, a 
meta-analysis using 11 studies yielded a large combined effect size for the benefit of exercise 
over control conditions when treating depression (d = 1.42) indicating that exercise can be a 
powerful intervention for clinical depression (Stathopoulou et al. 2006). A recent review of 
studies investigating the relationship between physical activity and depressive symptoms reveal 
an inverse relationship between physical activity and depression and that even a low dose of 
exercise can reduce the probability of developing depression (Teychenne et al. 2008).  
It has been well established that exercise is a therapeutic intervention with proven benefits in the 
treatment of depression however its mechanisms of action remain unclear.  
2.10.1  Exercise, neurogenesis and the hippocampus 
There are broad speculations as to the possible mechanism which exercise might impact aspects 
of cognition such as episodic memory.  Adult hippocampal neurogenesis has been suggested as a 
target for the amelioration or prevention of mental illness (DeCarolis and Eisch 2010). Voluntary 
exercise increases cerebral blood flow in the DG of the hippocampus and has been associated 
with increased adult hippocampal neurogenesis  (van Praag et al. 1999; Pereira et al. 2007). For 
instance, in mice the number of proliferating cells detected by bromodeoxyuridine (BrdU) 
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injections over 12 consecutive days increases significantly in runners compared to sedentary 
controls (van Praag et al. 1999). The positive association between voluntary exercise and 
increased adult hippocampal neurogenesis in rodents has been consistently replicated (van Praag 
et al. 1999; Pereira et al. 2007; Ekstrand et al. 2008; Fuss et al. 2010). Running also increases the 
volume of the rodent hippocampus after 8-10 weeks of voluntary exercise (Rhodes et al. 2003). 
Rhodes et al., (2003) suggest that increases in hippocampal neurogenesis might underlie the 20% 
hippocampal volume increase observed after 8-10 weeks of exercise. A possible mechanism by 
which exercise may increase hippocampal neurogenesis is increased cerebral blood volume.  
Cerebral blood volume, an in vivo correlate of neurogenesis and a potential mechanism, is also 
increased in the hippocampus and correlated with improved memory after a 3 month exercise 
intervention in mice (Pereira et al. 2007). 
Hippocampal neurogenesis has been linked to learning and memory improvements (Leuner et al. 
2006; Winocur et al. 2006) and it facilitates LTP in the hippocampus of adult rats (Farmer et al. 
2004). In rodents, exercise increases synaptic plasticity and improved retention on tasks 
mediated by the hippocampus (van Praag et al. 1999; Kramer and Erickson 2007) and enhanced 
the rate of learning on hippocampal mediated spatial navigation tasks such as the Morris Water 
maze swimming task that require the use of cues to determine the location of submerged escape 
platforms (Adlard et al. 2004). 
A recently published three month exercise study with schizophrenic patients and healthy controls 
found significant increases in hippocampal volume in both normal and schizophrenic patients 
which correlated with improvements in aerobic fitness and no change in a non-exercising 
schizophrenic group.  In the schizophrenia exercise group only, hippocampal volume increase 
was associated
 
with a 35% increase in the N-acetylaspartate to creatine ratio
 
(considered a marker 
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of healthy neurons) in the hippocampus. Short-term memory improvement correlated with 
change in hippocampal volume across all groups (Pajonk et al. 2010).  
2.10.2   Exercise, inflammation and growth factors 
Compelling evidence suggests that exercise training diminishes inflammation (Beavers et al. 
2010). Exercise promotes an increase in the systemic levels of a number of cytokines with anti-
inflammatory properties and therefore protects against chronic medical disorders associated with 
low-grade systemic inflammation (Petersen and Pedersen 2007). Specifically, studies have found 
that exercise not only decreased the levels of pro-inflammatory cytokines IL-6, TNF-α, and CRP 
but also simultaneously elevated the concentrations of anti-inflammatory cytokines IL-4, IL-10 
and TGF-β when compared with controls.  IL-4, IL-10 and TGF-β are not only anti-
inflammatory in nature but also inhibit the production of pro-inflammatory cytokines IL-1, IL-2, 
and TNF-α  (Das 2004; Das 2006) . Exercise also sets into action an interactive cascade of 
growth factor signalling that has the net effect of stimulating neuroplasticity, enhancing 
cognitive function, attenuating the mechanisms promoting depression, up-regulating 
neurogenesis and increasing cerebrovascular perfusion (Cotman et al. 2007). For example, IGF-1 
signalling converges on BDNF signalling, which may explain the positive effects of exercise on 
both memory and depression. Exercise may also improve growth factor signalling by reducing 
pro-inflammatory cytokines and directly increasing growth factor levels (Cotman et al. 2007; 
Petersen and Pedersen 2007). BDNF, IGF-1 and VEGF are the main growth factors known to 
mediate the effects of exercise on the brain (Trejo et al. 2001; Vaynman et al. 2004; Cotman et 
al. 2007). The effects of exercise on memory, learning and depression are primarily regulated by 
IGF-1 and BDNF, whereas exercise-dependent stimulation of angiogenesis and hippocampal 
neurogenesis appear to be regulated by IGF-1 and VEGF (Cotman et al. 2007). 
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Supporting the critical role of the VEGF signaling pathway in neurogenesis, researchers 
compared depression-like behaviour, blood vessel density, and neurogenesis in hippocampal DG 
between stressed and exercising mice with or without administration of VEGF receptor inhibitor. 
Chronic stress led to the development of depression-like behaviour, decreases in blood vessel 
density and neurogenesis in the hippocampus, whereas regular exercise training improved 
depression-like behaviour, limited the decrease of hippocampal blood vessel density and 
enhanced the survival of newly generated neurons in chronic stress.  Interestingly the 
combination of exercise and VEGF receptor inhibitor cancelled the exercise-induced 
antidepressant effect (Kiuchi et al. 2012).  
2.10.3   Further evidence for exercise and neural function 
Exercise enhances cognition and brain function, protects against the development of 
neurodegenerative diseases and aging (Dishman et al. 2006; Kramer and Erickson 2007) and has 
been shown to improve sleep quality (Atlantis et al. 2006). Descriptive studies have found that 
elderly adults with greater levels of physical activity are less likely to develop dementia or other 
cognitive function impairments compared to those who do not exercise (Kramer and Erickson 
2007; Rosano et al. 2010). For instance, aerobic exercise improves cognitive function in aging 
humans (Colcombe et al. 2003) and has been associated with the sparing of brain tissue in 
humans (Colcombe et al. 2006). Also, physical activity and higher fitness levels in elderly 
individuals are associated with increased hippocampal volume and better memory function 
(Erickson et al. 2009).  Importantly, physically fit individuals are reported to have larger left and 
right hippocampal volumes than unfit individuals. Furthermore, hippocampal volume increases 
following an exercise protocol are partially mediated the relationship between higher fitness 
levels and enhanced spatial memory in older adults (Erickson et al. 2009). In elderly humans, 
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persistent physical activity has also shown to increase psychomotor speed as well as increased 
brain activation (Rosano et al. 2010). Moreover, aerobic exercise has also been associated with 
delaying the onset of and decline in several neurodegenerative diseases (Cotman et al. 2007) and 
known to facilitate neurocognitive recovery from traumatic brain injury(Devine and Zafonte 
2009; Mossberg et al. 2010).  
In addition to the observed structural changes in the brain, research has found that exercise can 
alter brain activity and functional connectivity associated with cognitive tasks (Voss et al. 2010). 
For instance, Voss et al., (2010) used fMRI to examine cognitive relevant brain networks before 
and after a 12 month aerobic exercise intervention in older adults. Researchers found that aerobic 
fitness training improved the aging brain‟s resting functional efficiency in higher-level cognitive 
networks. Additionally, changes in functional connectivity was associated with a behavioural 
change such that increased functional connectivity was correlated with greater improvement in 
executive function (Voss et al. 2010). 
It is quite clear that exercise sets into motion an interactive cascade of biological events that has 
a net effect of stimulating neural plasticity and neurogenesis, improving cognitive function, and 
attenuating the mechanisms that drive depression (Cotman et al. 2007). Both human and animal 
findings suggest that exercise targets many areas of brain function and has a wide array of 
positive effects on overall brain health, resilience, memory and learning, and depression (Cotman 
et al. 2007).  
Exercise is a new and promising low-cost approach to preserve and protect CNS health. Exercise 
may be a viable treatment option in treating depression because it can be recommended to most 
individuals and does not carry a negative social stigma as the other treatment therapies do (Dunn 
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et al. 2005)  . Research must identify treatment targets and directions for future studies to 
identify individuals at risk, decrease relapse rates, and increase long-term favourable outcomes 




Chapter 3  Methods  
 
3.1 Experimental design for future pilot study 
This future study will utilize a cohort control design.  Participants will be recruited in blocks.  
Group 1 will undertake a 12 week structured, supervised exercise program in addition to the 
LMHDT and they will be recruited in the first year of the study.  Group 2 from the LMHDT will 
be recruited in the second year so that they can be matched by age, gender, pharmacotherapy and 
baseline fitness level to the exercise group using the same inclusion criteria.  
The reason for running the study as a cohort control rather than a randomized control trial is that 
the LMHDT is a group program and it might affect group cohesion if some participants were 
offered the exercise program and others were not.  This way everyone in the first cohort who 
meets the inclusion criteria will be given the opportunity to have the exercise program, and this 
will not interfere with the program in the way that it is currently run.  It also allows us to age and 
gender match the non-exercising LMHDT cohort (group 2), as well as a cohort of non-depressed 
individuals who will undergo baseline fMRI scans to provide normative data for comparison for 
potential fMRI activation changes in the depressed groups. 
Outcome measures will be assessed at baseline and week 12 (see Figure 3.1). The primary 
measures are salivary cortisol, hippocampal activation during a memory task, plasma biomarkers 
and depression scores. Additional measures will include subjective exercise barriers and self-
efficacy questionnaires, a face recognition task evaluating hippocampal function, a 
cardiorespiratory fitness test, sleep quality questionnaire and a neurocognitive screening test. 
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Additionally, a precursory investigation will be carried out in a group of non-depressed, active 
participants, to determine „normal‟ values. 
A sedentary non-depressed group will be recruited from UOIT and Durham College in Oshawa 
Ontario. Advertisement will be placed throughout the campus. Participants will complete the 
same assessments as the depressed groups at baseline and week 12.  They will receive the same 
12 week exercise intervention as the depressed exercise group. The non-depressed control group 
will provide background data on the normal values and variability of the measures in an 
asymptomatic group, with particular focus on cortisol and hippocampal function in addition to 
the effects of exercise on non-depressed sedentary adults. This will enable studies to discriminate 
the general effects of exercise on neural function and biomarker status as distinct from those 
unique to depression. 
For the non-depressed group, respondents to recruitment advertisements received the Participant 
Information Sheet (PIS), orientation session, consent form, Par Q, Baycrest Screening Form, and 
the following questionnaires: BDI-II, HADS, MoCA, PSQI (section 3.2.2, Appendices 1-8). 
Those who met inclusion criteria attended a baseline assessment, exercise self-efficacy 
questionnaires, the Astrand-Ryhming fitness test, first set of salivettes accompanied by saliva 
sampling instructions (Appendix 9), blood collection and fMRI. At this stage, the participants 
will commence the exercise program, completing three sessions per week. In week 12, all 
questionnaires, neurocognitive assessment, fMRI, fitness test, saliva samples and blood 










Figure 3.1: Overview of study design for the depressed exercise group, depressed control group and non-
depressed exercise group. 
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3.2 Selection of outcome measures and protocols 
3.2.1 Variables 
Independent variables 
1) Exercise intervention 
 Relative training intensity (% HRmax) 
Dependent variables 
1) Psychometric evaluation 
 BDI-II - depression rating (out of 63) 
 HADS - anxiety and depression ratings (each out of 21) 
 MoCA - screens for mild cognitive impairment (out of 30) 
 PSQI - Sleep quality rating (out of 21) 
 Barriers and exercise self-efficacy (each out of 100) 
2) fMRI 
 Blood oxygenation level-dependent (BOLD) response 
3) Associative memory task 
 Hippocampal function – accurate responses (high and low confidence) 
4) Salivary cortisol 
 Absolute levels at awakening, 30 minutes post awakening (nmol/L) 
 Wakening response – increase in secretory activity following awakening (Edwards et al. 
2001) 





6) Anthropometry  
 Body mass (kg)  
 BMI (kg∙m-2) 
7) Astrand-Ryhming protocol 







Presently, immunoassays are the most widely used techniques measuring cytokines and growth 
factors in human serum and plasma because of their high specificity, sensitivity, rapid 
turnaround time, convenience, the ease of performance and relatively low costs (Sachdeva and 
Asthana 2007). Their detection limit is approximately 1-5 pg/ml and they have good 
reproducibility with a coefficient of variation between 5-10% (Sachdeva and Asthana 2007). The 
basic cytokine sandwich ELISA based method is a monoclonal antibody specific for each 
antigen is pre-coated onto a microplate containing 96 wells. Standards, controls and samples are 
pipetted into the wells and any biomarker present is bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody specific for each 
antigen is added to the wells. Following the wash to remove an unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and color develops in proportion to the amount 




Salivary cortisol  
Salimetrics Oral Swab (SOS: Salimetrics
®
, State College, Pennsylvania) for saliva collection is 
an excellent alternative to passive drool because of its ease of use. The SOS is made of a non-
toxic, inert polymer shaped into a 30 x 10 mm cylinder. (Salimetrics 2006; Salimetrics and 
Europe 2011). 
Enzyme immunoassay (EIA) is an acceptable widely used method for determining salivary 
cortisol (Gozansky et al. 2005). This method is advantageous due to the high sensitivity, ease of 
use, rapid detection and also avoiding the disposal and lifetime issues associated with using 
radioisotopes (Blackburn et al. 1991). 
Beck Depression Inventory – Second Edition (BDI-II) 
The BDI-II (Appendix 5) is a 21-item self-reported instrument that corresponds to the criteria for 
depressive disorders from the Diagnostic and Statistical Manual of Mental Disorders – Fourth 
Edition (DSM-IV; American Psychiatric Association, 1994).  Each multiple choice question is 
rated on a 4-point scale of 0-3, ranging in intensity. Total numerical scores are compared to a 
classification key with higher scores indicating greater depression severity. Total depression 
scores of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe (Beck et al. 
1996). The BDI-II has demonstrated high internal consistency (0.92 and 0.93, respectively), test-
retest reliability of 0.93 (p < .001), and has found to have significant correlations (r = 0.68 - 0.93) 
with three other major instruments used in the assessment of depression in samples of psychiatric 
outpatients and University students (Beck et al. 1996).  
Hospital Anxiety and Depression Scale (HADS) 
The HADS (Appendix 6) developed by Zigmond and Snaith (1983), is a 14-item self-report 
instrument, that assesses anxiety and depression (Snaith 2003). Seven items measure depression 
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and seven items measure anxiety. Each item is rated on a four-point Likert scale of 0-3, and each 
subscale has a total possible score of 21 (Snaith 2003). Although there is no set standard of 
cutoff scores (Herrmann 1997), authors recommend that a score of 0-7 is considered within the 
normal range, 8-10 indicates a possible case of the respective mood disorder, and a score higher 
than 11 indicates a probable case.   
The HADS has demonstrated good validity and reliability against clinical diagnosis of 
depression (Mykletun et al. 2001) and has consistently demonstrated high test-retest reliability 
(r>0.80) (Herrmann 1997). Internal reliabilities for the anxiety and depression subscales, and 
total score have been reported as (Cronbach α‟s) 0.82, 0.77, and 0.86 respectively (Crawford et 
al. 2001). While the average sensitivity and specificity has been reported as 0.8 or higher from 
17 different studies (Herrmann 1997). 
Exercise Self-Efficacy Scale  
The 11-item questionnaire (Appendix 10) developed by McAuley and colleagues (1990), 
measures perceived capabilities to exercise three times per week when faced with barriers. Each 
item is rated on a scale of 0-100 then averaged to give a total score out of 100. The measure has 
demonstrated high internal consistency (α = 0.92) and has been shown be predictive of exercise 
adherence (McAuley et al. 1990). The rationale for administering this scale is to help the RC 
identify and consider barriers that may prevent participants from adhering to the exercise 
program.  
6-item Exercise Self-efficacy Questionnaire 
The six-item questionnaire (Appendix 11) was developed and validated by Litt and colleagues 
(2002) to assess the confidence in ability to adhere to an exercise program over an extended 
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period of time (one and fours weeks). Each item is rated on a scale of 0-100 then averaged to 
give a total score out of 100. The measure has demonstrated high internal reliability (α = 0.97). 
The rationale for administering this scale is to identify participants with a low self-efficacy for 
exercise that may need extra supervision or encouragement so that the maximum exercise 
sessions can be completed. 
Pittsburgh Sleep Quality Index (PSQI) 
A sleep quality measure is a valuable tool, since poor sleep quality is associated with depression 
and HPA axis dysregulation (Backhaus et al. 2004). The PSQI (Appendix 8) developed by 
Buysse and colleagues (1989) is 19-item questionnaire that assesses sleep quality during the 
previous month. Seven components of sleep quality are measured including, subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
sleeping medications, and daytime dysfunction. Scoring of the answers is based on a 0 to 3 
Likert scale where 3 reflects decreased sleep quality and a global sum of five or greater indicates 
a poor sleep quality for a total possible global of score of 21 (Buysse et al. 1989).  
The PSQI demonstrates both high internal consistency (α = 0.83),overall test-retest reliability 
0.85 (p = 0.001) and was able to differentiate between healthy, depressed and sleep disorder 
groups, even after covarying for age and gender, with a sensitivity of 89.6% and a specificity of 
86.5% (Buysse et al. 1989). 
Montreal Cognitive Assessment (MoCA) 
The Montreal Cognitive Assessment (MoCA) is a brief neurocognitive tool with high sensitivity 
for screening patients with mild cognitive impairment (Nasreddine et al. 2005). This cognitive 
assessment was given to identify participants who may have difficulty performing the associative 
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memory task. It scores from 0 to 30, where higher scores indicate better cognition and a score 
below 26 indicates cognitive impairment corresponding to mild cognitive impairment (Appendix 
9). 
Associative Memory Task:   
To evaluate the encoding and retrieval processes of memory, fMRI studies frequently use a 
recognition memory paradigm that consists of a „study‟ and „recall‟ phase (Sperling et al. 2003; 
Henson 2005). An associative memory paradigm using face name pairing was used to investigate 
functional abnormalities of the hippocampus during the encoding process (Sperling et al. 2003; 
Fairhall et al. 2010). A specific version of a face recognition task known to reliably activate the 
hippocampus during encoding (p<.001) was used (Sharma 2007). The inclusion of confidence 
judgments during the testing phase was used to account for successfully remembered items and 
not lucky guesses (Henson 2005).   
A LCD projector and rear projection screen was used to present the encoding task during the 
functional image acquisition. During encoding, participants viewed 240 face name pairs over two 
nine minute fMRI sequences. To ensure adequate encoding of the stimuli and participant 
engagement, participants were asked to indicate whether they felt the name suited face. 
Participants responded using a push-button response box. Each sequence consisted of the 
presentation of jittered event related face name pairs with 120 stimulus presentations of 3 s, 
interspersed with 34 fixations periods varying between 3 and 9 s. The retrieval task was 
performed outside the scanner on a laptop computer. Participants were first asked to indicate 
which of the two names was originally paired with the presented face and subsequently asked 
after each judgment if participants were confident or not in their recollection (see Figure 3.2). 
This allows for the post hoc coding of events during the encoding phase that led to a strong 
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memory formation. This information is then used to separate fMRI data into successful 
(confident-correct responses) and unsuccessful (incorrect) events. This procedure has been used 
by researchers (Sperling et al. 2003; Fairhall et al. 2010) and has revealed that activation in the 
right anterior hippocampus is tightly coupled to encoding success. Participants were presented 
with different face name combinations at 0 and 12 weeks to control for the effects of both time 
and of practice among the three groups. 
 
Figure 3.2: Associative memory task 
 
MRI/fMRI Protocols 
Participants were scanned at the Rotman Research Institute, Baycrest Centre, Toronto, Ontario in 
a Siemens Magnetrom Tim Trio Whole Body 3T MR scanner with a 32-channel Avotech Audio 
head coil. The participant‟s head was restrained using a vacuum pillow that fit inside the head 
coil. To maximise hippocampal signal quality, slices were positioned perpendicular to the long 
axis of the temporal lobe on an oblique coronal orientation, with phase encoding in the foot to 
head direction. The MR session included six series of scans. See Table 3.2 for scan details. 
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For functional scans, 50 oblique coronal 3.5 mm slices with full brain coverage were obtained 
(TE=27 ms; TR=2.5 s; flip angle 70⁰; FOV=200 mm; resolution=3.125x3.125x5mm; zero gap 
using T2*-weighted EPI sequence). Anatomical images were obtained following the fMRI 
consisting of 3D T1-weighted pulse sequence (TE=2.63 ms; TR=2 s; FOV=256 mm; 1 mm 
isotropic voxels; 176 slices).   
Table 3.2: fMRI protocol 
MR Series Data Aquisition Time 
1. Auto align scout Slice positioning 00:00:46 
2. Localizer Slice positioning 00:01:26 
3. fMRI BOLD at rest 00:09:00 
4. fMRI BOLD during memory encoding task 00:09:00 
5. fMRI BOLD during memory encoding task 00:09:00 
6. MRI structural 00:06:26 
Instructions between series  00:03:00 
Set up  00:15:00 
Total scanner time  00:53:38 
  
Stimuli were presented using E-Prime software version 2.0 (Psychology Software Tools). Images 
were back-projected onto a screen behind the scanner and shown to the participant using a mirror 
mounted on the head coil. The display had a spatial resolution of 1024 x 768 pixels and a visual 
angle of approximately 14.8⁰ x 12.1⁰ at a viewing distance of 132 cm.  
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Total time for each scanning session was under one hour (see Table 3.2).  Behavioural tasks and 
fMRI were synchronized according to trigger pulses sent by the scanner. For vision correction 
MR safe glasses made by SafeVision (Webster Groves, MO, USA) were provided. Participants 
responded with the right index and middle fingers using buttons on a Fiber-Optic Response Pad 
System paddle developed by Current Designs Inc. (Philadelphia, PA, USA).  
Astrand-Ryhming cycle protocol 
The Astrand-Ryhming cycle ergometer protocol is a six minute submaximal exercise test capable 
of estimating VO2max from heart rate (HR) measurements and perceived exertion (Whaley 2006). 
It is a single-stage test, with HR measured in the fifth and sixth minute (Whaley 2006).  The 
average of these values is adjusted for age using age correction factors, and an estimation of 
VO2max is made using a specifically-designed nomogram (Astrand 1960; Whaley 2006, cited in 
Whaley, 2006). 
Cardiovascular fitness was assessed by the RC and final year kinesiology internship students at 0 
and 12 weeks. The prescribed intensities of the exercise program in this research are at a level 
that should lead to improvements in cardiovascular fitness if undertaken correctly. It is expected 
that cardiovascular fitness will improve in the exercise groups, and not in the MHDT control 
group.   
Body mass index (BMI) 
BMI provides a relative anthropometric measurement that is sensitive to changes over time. BMI 
values were obtained by dividing body weight in kilograms by height in metres squared (kg∙m
-2
), 
(Whaley 2006). The „normal‟  BMI range is 18.5 – 24.9 kg∙m
-2




Review of the literature suggests that both aerobic and resistance exercises are effective in the 
treatment of depressive disorders (Pedersen and Saltin 2006).  For the aerobic component, an 
initial intensity of 12-13 on the Borg Scale of Perceived Exertion (RPE) is recommended for a 
duration of 10-20 minutes, gradually increasing to 15-16 RPE for 30 minutes (Pedersen and 
Saltin 2006). Using maximum heart rate (Whaley 2006), to determine intensity, it is suggested 
that a minimum of 70% HRmax is necessary to solicit greater improvements (Dunn et al. 2001). A 
higher total weekly energy expenditure, obtained through manipulating frequency, duration and 
intensity, has been shown to be significantly more effective in the treatment of mild to moderate 
severity depression (Dunn et al. 2005).  
Guidelines for resistance training in healthy adults recommend an 8-12 repetition maximum, 
with large-muscle and multiple-joint exercises being performed before small-muscle and single-
joint exercises, and increases of 2-10% (equivalent to around 1-2 repetitions) implemented 
before load is increased (Kraemer et al. 2002). 
3.3 Participants 
3.3.1 Recruitment 
It is important to differentiate the benefits of group exercise which are specific to exercise as 
opposed to the psychosocial benefits due to the social interaction that occurs within the group.  
The LMHDT provides an ideal solution to this.  Participants are referred into this program by 
psychiatrists at Lakeridge Health with a DSM-V axis I diagnosis of depression and sometimes 
concomitant anxiety. Upon referral all participants are screened to determine if there is a history 
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of substance abuse, internal mental distress, behaviour complexity or crime and violence using 
the GAIN-SS (Dennis et al. 2006), a validated tool designed to identify individuals who are 
likely to have a mental health and/or substance use disorder and who should be referred for 
further assessment or treatment. Participants with concomitant substance abuse disorders were 
not included in this feasibility study and will not be included in either arm of the pilot study. 
Participants will also undergo the SCID-I to confirm the clinical diagnosis of major depression. 
This will be administered by either the referring psychiatrist or the clinical psychologist. The 
SCID-I has excellent inter-rater and longitudinal reliability (Zanarini and Frankenburg 2001). 
The LMHDT is a 12 week program which includes a four week transition phase where 
participants meet twice per week, followed by six weeks of intensive group work focused on 
interpersonal relationships, depression, anxiety and stress management, relaxation, self-esteem 
building, communication skills, symptom management, goal setting / problem solving, mental 
health and substance use and community linkage.  Participants then have a further two week 
transition out of the program where they meet once or twice per week. 
Participants in this program will be offered the opportunity to participate in a structured 12 week 
exercise program in addition to the LMHDT and their results will be compared to a control group 
who has undergone the LMHDT but not exercised.  The exercise cohort will be recruited in the 
first half of the study so that the study may age and gender match the control group in the second 
half of the study.  This design also maintains the integrity of the LMHDT in that participants 
won‟t feel that other people in their therapeutic group are getting something that they aren‟t. 
Matched control participants will also be recruited from UOIT and Durham college for the non-
depressed exercise group. 
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An objective for this feasibility study was to develop a recruitment process that minimizes the 
number of steps required for both Lakeridge staff and potential participants. Following an 
expression of interest, potential participants underwent a Pre-screening questionnaire (see 
Appendix 7) administered by Lakeridge staff. Those who were still eligible at this stage were 
given an Information Session Invitation (see Appendix 1) and their contact information was 
forwarded to the RC for further screening.  Additional screening of participants was conducted 
over the telephone by the RC which consisted of the Baycrest Screening Form, and Par-Q. All 
eligible participants were then invited to a face-to-face screening interview and study orientation 
with the RC to ascertain their eligibility for the study. This included reviewing and signing 
Baycrest Screening Form and PAR-Q. Based on the official recommendations of the Canadian 
Society for Exercise Physiology (CSEP) and Health Canada if participants answer yes to any 
questions on the PAR-Q, they will be given a letter addressed to their physician (see Appendix 
12) explaining the study along with the PARmed-X (see Appendix 13) and they must receive 
clearance by their physician to enrol in the study.  Participants satisfying all criteria provided 




Figure 3.3: Participant recruitment process 
 
Lakeridge staff  administer the following measures to 
interested and eligible LHDT participants: 
1. BDI 
2. SCID 
3. Pre screening questionnaire 
4. GAIN-SS 
 
Eligible participants are given Study Information 
Invitation and their contact information is forwarded to 
RC 
RC telephones eligible participants to perform further 
screening:  
1. Telephone Screening Questionnaire 
2. Par-Q 
2. Baycrest Safety Screening Form  
Eligible participants meet RC at UOIT Flex Center for a 
study orientation session.  
1. Powerpoint presentation 
2. Tour of the gym facility 
PARTICIPANT SIGNS CONSENT FORM 
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3.3.2 Inclusion/exclusion criteria 
Inclusion criteria for depressed group 
 Male or female, age 18-50 
 DSM-V diagnosis of major depression confirmed by the SCID-I interview 
 BDI score ≥ 20 
 Depression symptoms minimum 6 months 
 Attending LHDT program 
 Concomitant pharmacological treatment must have been stabilized four weeks prior to 
study enrolment 
 Currently sedentary (exercise less than 20 minutes, three times weekly) 
Exclusion criteria for depressed group 
 Medical contraindications to exercise, without relevant medical clearance 
 Co-existing DSM-V Axis I apart from anxiety (APA, 1994) 
 Participants who screened positive for substance abuse 
 Religious or cultural beliefs that prevent the collection of bodily fluids 
 Personal decision to withdraw  
Inclusion criteria for non-depressed group 
 Male or female, age 18-50 
 Currently sedentary (exercise less than 20 minutes, three times weekly) 
Exclusion criteria for non-depressed group 
 Any potentially confounding medical conditions (including, but not limited to, diabetes, 
chronic fatigue, any DSM-IV Axis I and II disorders) 
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 Evidence of depressive symptoms (BDI score >13), or anxiety (HADS anxiety subscale 
score >7) 
3.3.3 Informed consent 
This study was approved by three ethics committees: University of Ontario Institute of 
Technology, Lakeridge Health and The Rotman Brain Research Institute/Baycrest. All three 
REB committees approved research ethics for the duration of one year with the option to renew 
in the subsequent year. Written consent (Appendix 2) was obtained from the participant at the 
study orientation session. They were assured they would not be identifiable from their individual 
data, and advised of their right to withdraw at any stage, without giving a reason. 
3.4 Procedure 
All measures (excluding fMRI and memory encoding and retrieval task) were conducted at 
UOIT. Psychometric assessments were administered by RC in the Flex Centre boardroom. Blood 
collection was performed in the UOIT laboratory by a Medical Lab Technician. Fitness 
assessment was conducted by a Certified Personal Trainer in the UOIT Kinesiology lab. A 
polystyrene bin with two saliva collection devices and saliva collection instructions (see 
Appendix 9) was given to participants to perform on the subsequent Wednesday morning 
immediately upon wakening. fMRI and memory tasks were performed at Baycrest Hospital. For 











RC meets study participant at UOIT Flex Center to 
administer: 
1. HADS 3. Exercise Barriers and Self-Efficacy  
2. PSQI 4. MoCA 
 
CORTISOL 
Participant is given two labeled SOS devices and 
cooler pack. Swabs are returned to RC at  first 
exercise session. 
BIOMARKERS 
Participant is taken to UOIT  medical laboratory for 
blood collection 
FITNESS ASSESSMENT 
Participant is taken to UOIT Kinesiology lab located 
for Astrand-Rhyming Cycle Ergometer test 
BRAIN IMAGING AND MEMORY TASK 
Participant meets RC at Baycrest Hospital for fMRI 






Questionnaires and neurocognitive assessment were administered by the RC in the UOIT Flex 
Centre boardroom. Each form was explained in detail by the RC. The entire process took 
approximately 30 minutes.  
Salivary cortisol 
Saliva samples were procured with an inert polymer non-citric acid collection device (SOS: 
Salimetrics
®
, State College, Pennsylvania). Participants received a polystyrene bin and a set of 
two SOS tubes. The SOS tubes were labelled „waking‟ and ‟30 min‟ to indicate sampling times, 
which were immediately upon awakening and 30 minutes after awakening. Instructions were 
given to place the cotton swab under the tongue and salivate for two minutes, replace the lid, and 
put straight into the freezer. Participants were instructed to follow standard sampling protocol 
(Clow et al. 2004; Salimetrics and Europe 2011): nil by mouth, except water, and no cleaning 
teeth, steroid inhalers or smoking between the two morning samples. This is all detailed in 
written instructions which was provided to participants (Appendix 9). Sampling took place on 
the Wednesday following the orientation session. Completed samples were returned in the 
polystyrene bin at a subsequent exercise session. Samples were immediately transported to the 
UOIT laboratory and stored in the in a -80°C freezer in the UOIT laboratory. 
Blood collection 
Peripheral venous blood was drawn in the UOIT laboratory by a medical lab technician. 
Collection times and other information that could affect biomarker levels such as illness or 
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infection were logged by the technician (see Appendix 14). A total of 35 ml of blood was 
collected from each participant by venipuncture into ethylenediaminetetraacetic 
acid (EDTA) tubes. Blood samples were prepared within 30 minutes by centrifugation (3000g 
for 5 minutes), and the fibrinogen containing plasma supernatant was aliquot into thirty 0.5 mL 
labeled tubes and stored at -85°C until assayed. A contingency plan using two freezers for 
aliquot storage was followed in the event of a power outage or freezer malfunction. 
Biomarker analysis 
On the day of analysis, plasma and saliva were thawed and brought to room temperature. Plasma 
samples were vortexed and saliva samples were centrifuged at room temperature 2500 rpm for 
15 minutes. All assays were conducted according to the manufacturer‟s protocols. The antigen 
levels of IL-6 and VEGF were measured using sandwich ELISA kits (Quantikine
®
HS, R&D 
Systems Inc., Minneapolis, Minn., USA). Salivary cortisol was measured using Salimetrics 
Expanded Range High Sensitivity Salivary Cortisol Enzyme Immunoassay kit (Salimetrics LLC, 
Philadelphia, PA). Briefly, standards, controls, and samples were pipetted into a 96-well 
microtiter plate coated with unconjugated antibodies to human IL-6, VEGF and cortisol. Plasma 
assays were incubated at room temperature then washed. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for each of these components was 
added to the wells, incubated at room temperature and washed again accordingly. Since the 
cortisol assay utilizes a competitive reaction, a horseradish peroxidase-conjugated cortisol was 
immediately added, incubated at room temperature and washed. Following a wash to remove 
unbound antibody-enzyme reagents, a substrate solution was added to the wells. Colour 
development for all the assays was stopped by a sulfuric acid and the intensity of the colour was 
measured by a microtiter plate reader within 10 minutes. Linear regression was performed on 
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plots of corrected absorbance at 450 nm for IL-6, VEGF and cortisol. The concentration of 
antigens in patient plasma and enzyme-linked cortisol was then quantified by interpolation from 
the standard curves. All assays were performed in duplicate and the average was reported. 
  
fMRI and memory encoding task 
MRI suite procedures were followed according to the Baycrest MRI suite procedures. A unique 
participant ID was assigned by Baycrest Subject Coordinator for each participant and scan time 
was reserved online through the Baycrest Resource Scheduler. Immediately upon arrival, 
participants were given a Baycrest parking pass and 25 dollar gas voucher from the RC. 
Participants arrived at the MR Suite 15 minutes prior to their scheduled scan time accompanied 
by the RC.  The MRI Screening Form with participant ID number was filled in and reviewed by 
the MR Technologist. Participants were required to remove all makeup, jewellery, metallic and 
electronic items and all clothing except for underwear and socks. A hospital gown tied at the 
back and a pair of trousers was provided for participants to change into. The MR technologist 
escorted participants into the magnet room and the RC in the control area from the testing room. 
The MR Technologist gave the participant a brief orientation of what to expect in the scanner. 
Participants were given a panic button to press in case they needed to be removed from the 
scanner for any reason.  During the resting state scan, participants were instructed to close their 
eyes but remain awake. During the memory encoding task (see Figure 3.2) participants were 
instructed to use their index finger to press the first button if the name suited the face and their 
middle finger to press the second response button to indicate if the name did not suit the face. All 
instructions were given by the RC and MR Technologist through a microphone/intercom system. 
Once the scan was complete the MR Technologist removed the participant from the scanner and 




Immediately following the scan, participants were taken to a Rotman Research Institute (RRI) 
testing room located in Baycrest Hospital to perform the retrieval task on a laptop computer 




Figure 3.4.1:  fMRI and associative memory task process 
 
BAYCREST PARTICIPANT ID REQUEST 




     RC reserves scan time online via Baycrest fMRI 
     Resource Scheduler 
PARTICIPANT MEETS RC AT BAYCREST HOSPITAL 
Participant arrives 15 minutes early to review 
Baycrest MR Screening Form with MR Technologist 
MRI PREPARATION 
Participant changes into hospital gown, removes all 
metallic objects, makeup, jewelry and is escorted by 
MR Technologist to the scanner.  
IMAGING-MEMORY ENCODING TASK 
     fMRI (encoding task) and structural MRI are 
     performed. Scanning time is approximately 53 
minutes  
MEMORY RETRIEVAL TASK 
     Once scanning is complete participant is taken to RRI       
     testing room to perform retrieval task. Task time is     
     determined by participant response time. 
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Astrand-Ryhming fitness test 
The cycle seat height was adjusted to allow minimal knee flexion (approximately 10°) at the base 
of the pedal phase. Participants cycled for two minutes until their heart rate reached 
approximately 120 bpm, when the test was then initiated. Pedal speed between 50-70 RPM was 
required and workload (watts) was selected based on age and gender recommendations (Table 
3.4).  HR and rating of perceived exertion (RPE) was measured in the final 10 seconds of every 
minute. This workload was maintained for at least six minutes, until two consecutively 
comparable HR were obtained with a difference less than 5bpm. Final HR was used to estimate 
VO2maxfrom a specifically-devised nomogram, using age correction factors. 
 
Table 3.4: Recommended workloads for Astrand-Ryhming cycle protocol  
                  (modified from Whaley 2006) 
 
Physical activity level Male/female Age Workload (watts) 
Sedentary Female <40 years 25 – 50  
Sedentary Female >40 years 25 
Active Female <40 years 75 – 100 
Active Female >40 years 50 – 75 
Sedentary Male <40 years 50 – 100 
Sedentary Male >40 years 25 – 50 
Active Male <40 years 100 – 150 






Based on the general consensus from studies that report an aerobic intensity of 60–80% of 
maximum heart rate and an exercise frequency of three 30-minute sessions per week for 8 weeks, 
for a significant improvement in depressive symptoms, the intervention consisted of three 
sessions per week of aerobic and resistance exercises over a 12-week period, for a total of 36 
sessions. Participants were eligible to be included in analysis if they attended at least 75% of 
these sessions. One of the three sessions was aerobic exercise only, and the remaining two were 
resistance exercise followed by a shorter aerobic bout. The latter were performed at least 24 
hours apart. Participants attended on an individual basis. All sessions began with a 5-10 minute 
aerobic warm-up, and were supervised by a Certified Personal Trainer. Participants were advised 
to bring a drink bottle and keep well hydrated. Opportunities were provided to make up missed 
sessions. 
Based on the participant‟s experience and ability, one resistance exercise was selected from each 
of the six categories – horizontal push, anterior lower body, vertical pull, posterior lower body, 
horizontal pull, and vertical push (Table 3.4.2) – in order to establish a balanced, whole-body 
prescription (see photos, Appendix 15). 
These exercises were performed as two or three paired supersets, in order to reduce the workout 
duration while still promoting adequate rest periods. The sessions utilised an 8-10 repetition 
range over three sets. To facilitate progression, participants were encouraged to increase their 
weights once they could perform three sets of 10 comfortably, reverting back to eight repetitions 
at the higher weight. Exercises were changed after four weeks, to avoid adaptation. The aerobic 





Table 3.4.2: Resistance exercise options, by category 
Category Exercise options 
Horizontal push Machine bench press 
DB bench press 
BB bench press 
Anterior lower body Machine leg press 
DB split squat 
Vertical pull Underhand pull down 
Overhand wide-grip pull down 
Overhand close-grip pull up 
Cable tricep extension 
Posterior lower body Machine leg curl 
One-leg calf raise 
Machine calf raise 
Horizontal pull Machine seated row 
DB row 
Machine preacher curl 
 BB biceps curl 
 DB jack-hammer curls 





All aerobic exercises were performed on either the cycle or treadmill. Workloads were 
determined by HR response, which was prescribed as 70-85% max. The full aerobic sessions was 
initially 30 minutes, and progressed in five-minute increments over the 12 weeks, up to 60 
minutes. Individuals could also progress their target HR within the prescribed range.  
At every session, information was recorded for each participant on average and maximum HR 
obtained, exercise duration, workload (watts, for the cycle, or speed and incline for the 




Statistical evaluation of the results for the psychometric measures, biomarkers and fitness 
assessment are presented as means, standard deviations (SD), ranges and percent change.  
3.5.1 fMRI analysis 
Data analysis procedure from Fairhall et al. (2010) was followed accordingly using SPM5 
software (www.fil.ion.ucl.ac.uk/spm/). All functional volumes were slice time corrected, 
realigned, smoothed (5mm kernel), high-pass (128 s) filtered and normalised to standard 
stereotactic (MNI) space (using the segmented grey matter). 
The analysis was based on a conventional general linear model (Friston et al. 1995). Three 
condition types were retrospectively nominated based upon whether the stimulus was matched to 
the correct name outside the scanner: with high confidence (HC correct), with low confidence 
(LC correct) or incorrectly. As the LC correct condition was uninformative, containing both truly 
correct responses and a high number of lucky guesses (chance = 50%), only HC correct and 
incorrect responses were taken to a second level factorial random effects design [group by 
encoding success] to permit inference at the population level. 
 
Chapter 4  Preliminary results 
4.1 Sample 
Table 4.1 provides the number of cases (N), means (M), standard deviations (SD) and ranges for 
the variables of interest. Five (N=5) LMHDT patients (one male and four females) with a clinical 
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diagnoses of MDD, confirmed by the SCID-I, and no other co-existing DSM-IV Axis I 
disorders, have enrolled in this research study thus far.  The mean age was 37.4 years (SD=10.2) 
with a range of 28 to 49 years. Attrition rate was 60% however since one participant dropped out 
at nine weeks it was decided to collect their post exercise measures. 
Of these five participants, three were medicated with a selective serotonin reuptake inhibitor 
(SSRI) and two were taking a serotonin-norepinephrine reuptake inhibitor (SNRI). In addition to 
antidepressant medications one participant was taking anti-inflammatory and 
immunosuppressant medications and one participant was taking psychostimulant and 
anticonvulsant medications. The mean depressive episode was 11.6 months (SD=10.6) however 
four participants reported suffering from depression for several years. The data set did contain 
missing data. Of the biomarker variables, one participant failed to provide a waking saliva 
sample and one baseline IL-6 data was excluded due to an elevation from a confounding case of 
acute otitis media.  
4.1.1 Psychometric evaluation 
The mean baseline BDI score (M=36, SD=2) indicates severe depression, the HADS-D (M=11, 
SD=3.16) indicates definite depression, the HADS-A (M=15.80, SD=2.28) indicates definite 
anxiety, the PSQI (M=11, SD=5.53) indicates poor sleep quality, and the MoCA (M=23.6, 
SD=2.10) indicates mild cognitive impairment. 
4.1.2 Biomarker data 
The mean waking salivary cortisol concentration (M=10.73, SD=9.75), the 30 minute post 
awakening (M=19.96, SD=13.82) and CAR (M=133.10, SD=164.50) are within the normal 
healthy range. Unfortunately, the mean group value is misleading and does not translate the 
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abnormal levels and CAR occurring within the sample. Figure 4.1 depicts the waking, 30 
minutes post awakening cortisol concentrations as well as the CAR for each participant 
compared to normal healthy values.  Compared to normal values, no participant‟s cortisol profile 
was within in the healthy range. 
The mean IL-6 plasma concentration (M=8.32, SD=5.07) indicates higher than normal values 
suggesting an inflammatory state. Contrary to our hypothesis the mean VEGF concentration 
(M=58.67, SD=15.34) is higher than the normal value. 
 
 












































4.1.3 Fitness scores 
Individual fitness scores are allocated based on age and sex. Therefore a mean group score does 
not indicate an overall group fitness level. This measure will be used at 12 weeks following the 
exercise program to determine the relationship between changes in estimated relative VO2max 
































































































































































































































































































































































































































































































































































































































































































































































































































































4.2 Change – Participant one  
See Table 4.2. 
4.2.1 Psychometric changes 
The BDI score decreased from 34 at baseline to 17 at week 12, a change of 51.4% (see Figure 
4.2.1). The HADS depression subscale score decreased from 12 to 5, a change of 58.3%. The 
HADS anxiety subscale score decreased from 16 to 14, a change of 12.5%. The HADS 
depression subscale score decreased from 1.6 to 0.9, a change of 3.3%. The PSQI score 















Normal - Mild depression
Mild - Moderate depression
Severe depression
 
Figure 4.2.1: Participant one change in depression scores following 12 week exercise intervention  
4.2.2 Biomarker changes  
The waking cortisol decreased from 23.7nmol/L at baseline to 5.7nmol/L at 12 weeks, a change 
of 76%. Cortisol levels post 30 minute awakening decreased from 38.1nmol/L to 10.3nmol/L, a 
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change of 73% (see Figure 4.2.2). The CAR increased from 60.5 to 80.7, a change of 33.5%. IL-
6 decreased from 7.82 µg /ml at baseline to 6.12 µg/ml at 12 weeks, a change of 21.76%. VEGF 



























Figure 4.2.2: Participant one change in cortisol following 12 week exercise intervention vs. mean normal 
values 
 
4.2.3 Fitness change 




) at baseline to 50.76 (mL∙kg-1∙min-
1
), a change of 114.29% (see Table 4.2). Based on age, sex and BMI these results indicate a 
maximal fitness change from the classification of needs improvement to the excellent health 








Table 4.2: Participant one results at baseline vs 12 weeks following exercise intervention. 
 


















Cortisol waking (nmol/L) 
Cortisol 30 min (nmol/L) 
CAR percent increase (%) 
IL-6 (pg/ml) 
VEGF (pg/ml) 












































    
 
 
4.2.4 fMRI analysis 
Recently, Fairhall et al. (2010) identified the network of brain regions involved in attempted 
encoding from the activation during an encoding task compared to baseline (fixation-events). 
Bilaterally, elements of the fronto-parietal attention networks and the ventral visual stream and, 
importantly, medial temporal lobe structures were activated (see Figure 2.2.4 A). In participant 
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one (Figure 4.2.4 C) a similar activation pattern in the medial temporal lobe structures, weighted 
towards the hippocampal complex rather than the parahippocampal gyrus, indicates that this task 
mainly recruited hippocampal structures. Activation has been colour coded into cortical (orange), 
hippocampal (red), parahippocampal (blue) and amygdalic regions (green) using anatomical 
templates (Tzourio-Mazoyer et al. 2002). All activations are thresholded at p < .001 and 
corrected for multiple comparisons at the cluster level. The yellow dot in the hippocampus 
represents the region extracted for further analysis (see Fig. 4.2.4 A). 
Previous pilot data (Fairhall et al. 2010) formally demonstrates that the strong relationship 
between hippocampal activation and encoding success present in normal subjects is absent in 
individuals experiencing MDD (Fairhall et al. 2010). Figure 4.2.4 (B) shows a significant group 
by group (Controls vs MDD) interaction within the bilateral anterior hippocampus. This 
interaction was driven by a positive association between hippocampal activity and successful 
encoding in non-depressed controls (left: t(7) = 2.83, p < .05; right: t(7) = 3.00, p < .05) that was 
not present in individuals with MDD (left: t(7) =−0.46, ns; right: t(7) =−0.44, ns.). To measure 
the difference in the relationship between encoding success and bilateral hippocampal activation 
in control and MDD groups, Cohen‟s d was calculated separately for each group. A large effect 
size (d= 1.11) was found for controls while depressed individuals showed no relationship 
between anterior hippocampus activity and stimulus encoding success (d=−0.19).  
For this feasibility study, a region-of-interest (ROI) approach was adopted from previous pilot 
work by Fairhall and colleagues. The peak voxel in left and right anterior hippocampi were 
selected from the contrast of task versus fixation-events irrespective of encoding success (see 
Figure 4.2.4 C). This comparison to the loose fixation-baseline allowed for the identification of 
eloquent-voxels in a way orthogonal to the effects of interest (i.e. condition, group). Results also 
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show that we were able to detect differences pre/post intervention with the data set from 
participant one. Figure 4.2.4 D illustrates a baseline result similar to the „MDD response‟ found 
in Fairhall et al. (2010) and the predicted pattern of increased activation in the anterior 
hippocampus during the associative encoding of stimuli that are later remembered with 
confidence following the 12 week exercise program.  
 
 
Figure 4.2.4: A comparison of fMRI results from Fairhall et al. (2010) and participant one. 
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Chapter 5  Discussion  
Despite the attempts of several theoretical models delineating the causes of depression, the 
pathogenesis remains elusive preventing the availability of treatments that target the causal 
factors. It has been well established that exercise is an effective treatment for depression 
however it is not clear on exactly how and why it works. The overall goal of this research is to 
investigate whether the mechanism by which exercise may improve depression is related to 
improving hippocampal function and if a supervised 12 week exercise program can promote 
changes in hippocampal function and improve memory in people living with depression. The 
purpose of this feasibility study was to develop comprehensive methods and validation of 
protocols to conduct our future pilot study. These included: 1) MDD participant recruitment from 
the LMHDT program; 2) fMRI protocol; 3) specimen collection and storage; 4) biomarker 
assays; and 5) an effective exercise program capable of improving depressive symptomatology.  
A preliminary results section was also generated based on data collected thus far. Although the 
sample size is too small to infer meaningful statistical results, our preliminary findings have 
raised several methodological concerns that will be discussed. 
Recruitment procedure  
To ensure that the sample population is a true representation of the MDD population, all 
participants recruited were diagnosed as clinically depressed based on DSM-V criteria confirmed 
by the SCID-I.  Our partners at the LMHDT program ensured that recruitment staff have been 
properly trained to administer the SCID-I. Additionally, to avoid unnecessary meetings between 
participants and RC, Lakeridge staff administered a pre-screening questionnaire provided by the 
RC to identify eligible sedentary, MRI safe participants. In support of these procedures, all five 
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participants recruited by Lakeridge staff have qualified for the study as confirmed by the 
additional screening measures and depression inventories administered by RC.  
Methods for specimen collection and immunoassays 
Well defined methods for specimen collection, processing and storage were established in 
accordance with laboratory procedures. The SOS was an effective device for obtaining copious 
saliva for cortisol analysis. Participants followed the saliva collection instructions provided to 
them and all samples were returned frozen and packed in their corresponding polystyrene bin. 
Given that immunoassays require very small samples volumes, plasma samples were divided 
into several small volume aliquots so that each aliquot could be assayed independently. This 
procedure proved to be very effective in minimizing plasma waste and avoiding the need for 
repeated freeze-thaw cycles. Additionally, the availability of several replicate aliquots will allow 
for further biomarker analysis and also increase reliability of assays by providing additional 
control samples to test inter- and intra- assay precision. All immunoassays were performed 
according to the manufacturers‟ protocols. Standard curves generated from each biomarker 
corresponded with the manufacturer values. Optical density values from each standard curve 
were also sent to the manufacturers for further verification.    
fMRI protocol validation 
Four fMRI pilot scans were performed to successfully validate the fMRI protocol previously 
piloted in New Zealand on a 1.5 Tesla General Electric MRI scanner using the 3.0 Tesla Siemans 
MRI scanner at the Rotman Baycrest hospital. Ideally this experimental paradigm will produce 
robust modulation of hippocampal activity with encoding success, separation of true encoding 
success from chance success and the selection of a specific brain region-of-interest. Baseline 
results from participant one indicates hippocampal dysregulation as data fails to show the 
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positive relationship between hippocampal activity and successful encoding as seen in the non-
depressed controls from Fairhall et al., (2010). Encouragingly, following the 12 week exercise 
program a more normalized pattern of hippocampal activation associated with successful 
memory encoding was observed. Taken together, these findings support the use of this 
experimental paradigm for future pilot work and also suggest that exercise may normalize 
hippocampal functioning in depressed individuals. If the study is able to show significant pilot 
results this may eventually lead to a potential in vivo biomarker for the functional integrity of the 
hippocampus in MDD to explore the relationships between 1) hippocampal dysregulation and 
clinical presentation, 2) hippocampal dysregulation and biomarker status and 3) the neurogenic 
effects of anti-depressant treatments such as pharmaceutical agents or exercise and the regulation 
of abnormal hippocampal function (Fairhall et al. 2010). 
Preliminary results 
Baseline psychometric data indicates that all participants were experiencing severe depression, 
anxiety, mild cognitive impairment and sleep disturbance. However 12 week results from 
participant one revealed the following improvements: severe depression to mild depression, mild 
cognitive impairment to normal cognitive functioning, and minimal improvements in anxiety 
score and sleep disturbance. 
The cortisol analysis yielded variable results across the group and no individual cortisol profile 
resided in the healthy normal range. Observations ranged from below normal to above normal 
levels and an absent CAR to an above normal CAR of 372%. Although these findings do not 
support our hypothesis that cortisol would be elevated in MDD, they indicate that depression is 
associated with a dysregulation in cortisol secretion.  Nonetheless, normal cortisol values were 
established in participant one following the 12 week exercise program.  
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Consistent with the literature the results show that depressed participants expressed higher 
plasma IL-6 concentrations compared with normal controls suggesting an inflammatory state. In 
support of our hypothesis, 12 week results from participant one show a decrease in IL-6 
concentration following the exercise program. An additional observation was that the participant 
with the highest depression score revealed the highest IL-6 concentration. Although it remains 
unknown whether exercise specifically targets pro-inflammatory cytokines, exercise may 
actually dampen the inflammatory processes through its immuno-regulatory/anti-inflammatory 
effects. An important issue that needs further evaluation may be the absence of counter-
balancing, immunoregulatory relationship between pro- and anti-inflammatory cytokines 
(Dhabhar et al. 2009). The future pilot study will include further analysis of additional pro-
inflammatory cytokines (IFN-γ - and TNF-α) and the anti-inflammatory cytokine IL-10 to seek 
these relationships.  
Compared with normal healthy individuals, VEGF concentrations were increased in depressed 
individuals.  Results from participant one showed a decrease in VEGF following the 12 week 
exercise program. These findings do not support the hypothesis or the neurogenic/neurotrophic 
hypothesis of depression which suggests that depression results partly from decreased 
neurotrophic growth factors. However the findings correspond with recent research findings that 
VEGF levels are higher in depression (Takebayashi et al. 2010)  and depression comorbid with 
borderline personality disorder (Kahl et al. 2009)  when compared to normal healthy controls. 
Other studies report no significant difference in plasma VEGF concentration were been found 
between medication-free MDD patients and controls (Ventriglia et al., 2009), and no alteration in 
VEGF plasma levels in medicated depressed patients during the courses of recovery (Dome et 
al., 2011). Studies have also found correlations with hormones and have reported higher levels of 
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VEGF in the follicular phase (Heer et al. 1998), the luteal phase (Agrawal et al. 1999), and 
significantly higher levels have been reported in postmenopausal compared with premenopausal 
women (Heer et al. 1998; Kim 1998) . Interestingly, the older female participants experiencing 
menopause in this study were found to have the highest VEGF levels (M=71.01) compared to 
those who were premenopausal (M=41.36). These findings highlight the critical gap in research 
that peripheral VEGF levels and brain VEGF levels have not been quantified in parallel in any 
psychiatric population. To shed some light, an animal model investigating the possible 
correlation of peripheral and central VEGF levels using a genetic rat model of depression, found 
that VEGF levels were identical in serum, corpus striatum, and hypothalamus whereas in the 
hippocampus and frontal cortex, the VEGF levels were significantly decreased in the depressed 
rats compared to the non-depressed rats (Elfving et al. 2010). The authors considered these 
findings to be salient since the frontal cortex and hippocampus are considered to be core brain 
regions involved in depression (Elfving et al. 2010).  
To further explore the relationship between exercise, neurotrophic factors and depression, the 
future pilot study will include additional growth factors (BDNF, IGF) known to be implicated in 
depression while eliminating VEGF for the reason that peripheral VEFG concentrations are 
influenced by several variables not associated with depression and do not correspond to VEGF 
levels in the CNS. 
Methodological confounds 
The high attrition rate of 60% indicates that the 12 week exercise program was difficult to adhere 
to for most participants. Two participants dropped out at seven weeks and one participant 
dropped out at nine weeks. A primary reason for withdrawal was that the LMHDT program 
ended two weeks prior to the exercise study and participants were returning to work. Since 
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research has shown that the benefits of exercise are reaped as early as eight weeks, it is 
recommended that the exercise program be reduced to 10 weeks. This will increased the 
probability of more participants completing the program.  
Disturbingly, a major barrier confronted while conducting this study was obtaining sound 
comparative normal and depressed biomarker data due to the extreme variability reported 
between studies. This warrants the need to standardize methods of biological sample collection 
and assays, otherwise using what is reported in the literature will be equivocal. 
Depression is a clinically and biochemically heterogeneous disorder. However, the majority of 
research examining the pathophysiology of depression have classified depression dichotomously 
either as yes/no or restricted the analyses to MDD when in fact there are several subtypes of 
depression which are based on the symptomatology (Baune et al. 2012). Subtypes of depression 
include dysthymia (a chronic, low-grade form of depression), melancholic MD (MMD) and MD 
with typical or atypical features (American Psychiatric Association 1994). Melancholic 
depression is characterized by anhedonia, lack of reactivity to pleasurable stimuli, reduced 
appetite, insomnia, and depression that is worse in the morning. In contrast, atypical depression 
is defined by appetite and weight increase, hypersomnia, fatigue and mood reactivity for positive 
events (Gold and Chrousos 2002). To further distinguish between subtypes of depression 
research has found that the principal arousal producing mediators of the stress response, such as 
CRH, are hyperactive in melancholic depression but not in non-melancholic depression (Gold 
and Chrousos 2002). Conversely, atypical depression and dysthymia (characterized by lethargy, 
fatigue, hypersomnia and hyperphagia) and have been associated with down regulated HPA 
activity and decreased cortisol levels (Griffiths et al. 2000; Hayley et al. 2005; Kaestner et al. 
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2005). Furthermore, increased inflammation has been found in non-melancholia depression and 
dysthymia but not in melancholic depression (Griffiths et al. 2000; Kaestner et al. 2005).  
In short, the majority of antidepressant medications target monoamine systems and have 
ultimately fallen short in successfully treating depression. There is now sufficient evidence in the 
literature to support the exploration of alternative therapeutic areas to target mechanisms 
associated with depression such as neuroendocrine function, immune regulation and 
neurotrophic factors (Berton and Nestler 2006; Kennedy and Rizvi 2009). In order to delineate 
specific mechanisms, biomarker or combination of biomarkers, several challenges in this field 
the following must be addressed: 1) the clinical variability within the syndrome of MDD; 3) the 
need to standardize methods of biological sample collection and assay; 4) longitudinal studies to 
better illustrate the relationships between depressive symptoms, neuroendocrine, inflammatory 
and neurotrophic markers. (Maes et al. 2009; Loftis et al. 2010; Blume et al. 2011). 
Personal observations 
Overall, participant compliance was excellent for all data collection methods. Participant 
feedback from the study was very positive indicating that saliva collection instructions were easy 
to follow and no barriers (lack of transportation) were associated with commuting to the Rotman 
Baycrest hospital for the fMRI scans.  On the other hand, participant compliance was poor for 
exercise attendance due to frequent tardiness for appointments and last minute cancellations and 
rescheduling which led to reduced trainer availability. Exercise attendance is a critical aspect of 
this study and trainer availability is essential. Therefore, a larger trainer pool is required for 
future pilot work to ensure trainer availability in the event of an inevitable schedule change.  
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Although participants were eager to participate in the study in hopes of curing their depression, 
participant anxiety was experienced during the initial exercise sessions. Feelings reported were 
poor body image and low self-efficacy for their exercise capabilities. To alleviate these anxiety 
provoking feelings associated with the initial exercise sessions, special attention must be given 
towards scheduling initial training sessions during the non-busy gym times or conducting initial 
training sessions in a private fitness room with only the participant and trainer.     
Finally, each personal trainer was assigned a participant for the entire exercise program. 
Consequently, it was noted that participant-trainer attachment bonds were formed by the 
participant during the 12 weeks. To prevent the formation of bonds and separation anxiety 
experienced by the participants following study completion, future pilot work must assign and 
rotate several trainers to each participant throughout the 12 week exercise program.  
 
5.1  Conclusion and recommendations  
Depression is a multifaceted, biochemically and clinically heterogeneous disorder that may 
account for some of the variability and unpredictability associated with treatments. The future of 
successful treatments for MDD is contingent on the ability to produce a „personalized medicine‟ 
paradigm (Kennedy and Rizvi 2009). Research must generate an integrative model illustrating 
how all the various targets interact. This will allow for a more precise exploration of 
neurobiological indicators of dysfunction and ultimately enable clinicians to identify and treat 
patients with specific dysfunctions based on their biochemical signature and clinical profile 
(Kennedy and Rizvi 2009).  
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Contrary to antidepressant medications, exercise is a treatment option that is linked to a myriad 
of therapeutic indications. Exercise sets into action an interactive cascade of biochemical 
reactions that has an overall net effect of stimulating neuroplasticity, enhancing cognitive 
function, normalizing HPA functioning, stimulating neurogenesis, improving cerebrovascular 
perfusion and improving immune function (Cotman et al. 2007). For researchers, this provides an 
optimal research setting to explore the broad assortment of biomarkers associated with the 
biological systems known to be altered in depression.  However, before any relationship findings 
can be inferred, methodological limitations must be addressed.    
First and foremost, the need to standardize methods of biological sample collection and assays 
must be established to minimize the variability between studies so that definite conclusions can 
be made. To increase assay reliability, it is recommended to prepare a normal human plasma 
bank from 15 normal healthy volunteers to create high volume plasma pools that can be used to 
test intra- and inter- assay precision. To ensure reproducibility between labs it is recommended 
that a plasma sample of known concentration be obtained from another institution using the same 
ELISA kits. 
As a final point, symptoms of depression differ markedly across individuals and subtypes of 
depression exist that may implicate different neurochemical substrates. Future studies must 
consider these differences and recruit individuals with a specific subtype and/or assign 
participants into homogeneous groups based on specific criteria.  Indubitably, future pilot work 
must categorize participants into depression subtypes and consider these subtypes during the 
hypotheses formulation and data interpretation. Otherwise specific relationships and significant 
findings will be lost in the compilation of heterogeneous results.  
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Appendix 1: Participant Information Sheet 
 
 
EXERCISE AND DEPRESSION STUDY  
 
Information Session Invitation 
 
Hello, 
We would like to invite you to come and hear more about a study that is being run by researchers 
in the Faculty of Health Sciences at UOIT and the Lakeridge Mental Health Day Treatment 
program. 
This research study is being conducted to study the effect of exercise on your levels of the stress 
hormone cortisol and a number of other biomarkers known to be altered in depression. We will 
also be looking at the way your brain functions during certain memory tasks.  We are interested 
in how exercise may change these things in depressed participants.  We are also interested in 
how exercise may affect the intensity of depression symptoms.  These will be assessed over the 
course of a 12 week structured, supervised exercise program, in addition to the treatment you 
already receiving as part of the Lakeridge Mental Health Day Treatment program.  The study 
will also involve two visits to a special MRI scanner at the Rotman Baycrest hospital.    
In order to be eligible for this study you must be a man or woman aged 18 to 50 years.  You must 
also currently be sedentary i.e  you exercise less than 3 times weekly for less than 20 minutes at a 
time.    
At the end of the information session, if you are interested in participating, we will get you to fill 
in some screening questionnaires to make sure that it is safe for you to exercise and that that you 
meet all the criteria to participate in this study.   
 
If you are interested in hearing more, please fill in your contact details and the researchers will 
get in touch with you.  
CONTACT INFORMATION 
What is your preferred way to be contacted?  Mobile Home Phone  Email 
Name   











Professor Bernadette Murphy 
University of Ontario Institute of Technology 
Faculty of Health Sciences 
2000 Simcoe St. North 
Oshawa, Ontario 
CANADA  L0B 1J0 
Email: Bernadette.Murphy@uoit.ca 




The role of exercise in improving brain function: Part A: Exercise MHDTP group 
 
You are invited to participate in a research study entitled “The role of exercise in improving 
brain function”.  This study (# REB 10-104) has been reviewed by the University of Ontario 
Research Ethics Board and has been approved as of July 6, 2011. Please read this form carefully, 
and feel free to ask any questions you might have. If you have any questions about your rights 
as a participant in this study, please contact the Compliance Officer at 905 721 8668 ext 3693 or 
compliance.uoit.ca. 
Researchers 
Dr. Bernadette Murphy, Professor, Head-Kinesiology Specialization, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2778, email: 
Bernadette.Murphy@uoit.ca, Fax: (905) 721-3179 
Dr. Paul Yielder, Professor, Director-Bachelor of Health Sciences, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2768, email: 
Paul.Yielder@uoit.ca, Fax: (905) 721-3179 
Dr. Nancy Wilkinson, Client Care Manager/Psychologist, Mental Health and Pinewood Program, 
Lakeridge Health, Phone: (905) 576-8711 ext 6233, email: nwilkinson@lakeridgehealth.on.ca 
Dr. Stephen Strother, Professor, Dept. of Medical Biophysics, University of Toronto, Senior 





Dr. Ron Heslegrave, Chair, Research Ethics Board, Baycrest, Phone: (416) 785-2500 ext. 2440, 
email: hesgrave@uhnres.utoronto.ca 
Joanne Gourgouvelis, Masters Student, Faculty of Health Sciences, University of Ontario 




Purpose of the Study 
This research study is being conducted to study the effect of exercise on your levels of the 
stress hormone cortisol and a number of other biomarkers known to be altered in depression. 
We will also be looking at the way your brain functions during certain memory tasks.  We are 
interested in how exercise may change these things in depressed participants.  We are also 
interested in how exercise may affect the intensity of depression symptoms.  These will be 
assessed over the course of a 12 week structured, supervised exercise programme, in addition 
to the treatment you already receiving as part of the Lakeridge Mental Health Day Treatment 
Programme.  Once this phase of the study is complete we will be recruiting a group of patients 
in the Mental Health Day Treatment Programme who are of a similar age and gender to 
investigate the effects of the Day Treatment Programme on its own in order to compare to the 
results of the exercise group. 
 
Potential Benefits to Participants and/or to Society 
Exercise has been shown in past studies to be an effective treatment for depression.  In this 
study we want to learn more about how and why it works in order to help us design the most 
effective types of exercise interventions.  Following the exercise programme, participants may 
receive additional relief from their depression.  This study offers a structured exercise 
programme suitable for beginners and may also help you resolve any physical issues you have.  
If we show a strong effect, it may become a future part of the Day Treatment Programme and 
you will be making an important contribution to improving treatment options for future 
patients. 
 
Participation and Withdrawal 
Your participation to take part in this study is voluntary.  You may choose not to participate or 
you may withdraw from the study at any time.  However, if you decide to stop participating in 
the study, we encourage you to talk to the study staff first.  The staff here is very flexible about 
meeting your needs and if there is anything we can do to accommodate your needs, we are 
more than willing to help.  You are still free to withdraw at any time without giving a reason, 
and your decision not to participate will not affect your care at this center.  
 
Rights of Research Participants 
You are free to ask any questions that you may have about your treatment and your rights as a 
research participant.  You may withdraw your consent at any time and discontinue participation 
without penalty.   
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If any questions come up during or after the study or if you have a research-related injury, 
contact the study researchers listed on the first page. 
 
Should you have any questions or concerns regarding your rights as a participant in this 
research study, or if you wish to speak with someone who is not related to this study, you may 
contact the Chair of the Lakeridge Health Corporation Research Ethics Board at (905) 576-8711 
or UOIT Research Ethics Board through the Compliance Office (905) 721-8668 ext 6393. 
 
You are one of 20 individuals being asked to participate in this study and have been referred to 
us by Lakeridge Mental Health Day Treatment programme with a diagnosis of depression and 
you are between the ages of 18 and 50.  Please take your time to review this consent form and 
discuss any questions you may have with the study staff.  You may take your time to make your 
decision about participating in this study and you may discuss it with your friends, family or 
your doctor before you make your decision.  This consent form may contain words that you do 






In order to be eligible for either group, you must not be currently doing regular exercise; that 
means your levels of exercise should be less than 20 minutes, three times per week.  People 
suffering from mental conditions other than depression, or with physical conditions that would 
prevent them from doing exercise, such as heart disease, will be excluded from the study. An 
understanding of English sufficient to answer questionnaires is required.   
 
If you have questions the stated procedures, timeline or exclusion criteria please feel free to 
discuss them with the study coordinator, Joanne Gourgouvelis or the investigators (contact 
details provided on page 1). 
 
The following sections will outline the various tests and procedures of the study, including: 1) 
the purpose of each test or procedure; 2) the respective timelines; 3) exclusion criteria (factors 
that might make you ineligible to participate);  
 
If you take part in this study, you will need to participate in several procedures.  Please read the 
following pages and tick the boxes to indicate if any of the exclusion criteria pertain to you:  1) 
Questionnaire completion (page 3),  2) Saliva samples (page 3),  3) Bloodwork (see page 4),  4) 
Brainscan (see page 5) 
5) Exercise (see page 6) 
You will also be loaned a special activity monitor to wear for the duration of the study in order 
to monitor your background activity levels.  The monitor straps on to your waist band and the 







1. Purpose  
To determine the severity of your symptoms associated with depression, you will 
complete some demographic information and you will then complete three 
Questionnaires, called the Beck Depression Inventory II (BDI-II) and the Hospital 
Anxiety and Depression Scale (HADS) and the Coping Self-Efficacy Scale.    
 
2. Timeline 
Questionnaires will be given at: 
i. Week 0 (prior to the exercise programme)  
ii. Week 12 (after completion of the exercise programme). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Do not understand English  
 
4. Risks:  There are no risks from completing these questionnaires, data will not 
contain any personal information that can identify you.  Privacy and confidentiality 




1. Purpose  
Cortisol is a hormone which is known to be elevated in depressed individuals, and 
chronically high levels of cortisol have been linked with changes in the way the brain 
functions.  It is possible that exercise may help depression by decreasing cortisol 
secretion. You will be given labelled tubes to collect a sample of your saliva (spit) to 
be tested at a laboratory for the stress hormone cortisol, which you will collect on 
the morning after your interview as soon as you wake up and then again 30 minutes 
after you wake up. The samples will then be put in the freezer and you will be given 
a small Styrofoam cooler to bring the samples back to the researcher on the next 
day that you attend the Lakeridge Programme. You will be given a set of simple 
instructions in case you forget what to do.   
 
2. Timeline 
Saliva samples will be taken at: 
i. Week 0: the day after your interview (when you wake up and 30 minutes after 
waking up) 
ii. Week 12: after completion of the exercise programme (when you wake up and 
30 minutes after waking up) 
 
 
3. Exclusion Criteria (please check box if you have any of the following) 
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i. Ulcers or sores in your mouth  
 
5. Risks  
i. There are no complications or side effects when collecting saliva.  Your samples 
will be coded in a way that does not identify you, frozen in a special freezer and 
stored until the end of the study.  They will be disposed of once they have been 




1. Purpose  
A number of biomarkers found in blood are also known to be altered in depression 
and exercise may act to normalize their levels. A technician from the Medical 
Laboratory Science Program at the University of Ontario Institute of Technology will 
collect blood samples from each participant twice during the study.  
 
2. Timeline 
Blood samples will be taken at: 
i. Week 0 (prior to the exercise programme)  
ii. Week 12 (after completion of the exercise programme). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Bleeding disorder  
ii. Medications that may interfere with blood clotting (heparin, wafarin)  
iii. Phobia of needles 
 
4. Risks  
Complications are very rare when acquiring blood samples through a sterile syringe. 
However, the following side effects have been reported: 
i. Excessive bleeding at site of puncture 
ii. Bruising 





Your blood and saliva samples will be coded in a way that does not identify you, frozen 
in a special freezer and stored until the end of the study when they will be analyzed.  
Any unused sample will be disposed of.  Once the samples have been analyzed and 






D. BRAIN SCAN (functional MRI) 
 
1. Purpose  
Prior to commencing your programme, fMRI images of your brain will be obtained to 
investigate the way that your brain activates when you are performing a task 
requiring your concentration.  We will also look at anatomical details of brain 
structures known to be involved in depression such as the hippocampus. Once you 
come out of the scanner, you will go to a separate room and be asked to go through 
some of the images from the task that you did in the scanner.  The scan will take 
about one hour and will be carried out at Baycrest hospital attached to the Rotman 
Brain Research Institute. We will then retest you at the end of your programme (12 
weeks) to see if exercise has changed the way your brain processes information.  
There will be no cost to you for the scans and you will be provided with parking and 
gasoline vouchers to cover travel costs for each session.   
The MRI scan being done is designed to answer research questions, not to examine 
your brain medically.  This MRI scan is not a substitute for one that a doctor would 
order, and it may not show problems that would be picked up by a medical MRI 
scan.   However, in the unlikely event that we note an atypical finding on your MRI 
scan, we will contact you to help you arrange medical follow-up to interpret the 
significance of the findings, if any.  We may also ask a radiologist, or other health 
professional, to look at your scan, and by signing this consent form you agree to 
releasing the scan for review.  It is possible that you could be unnecessarily worried 
if a problem were suspected, but not actually found.  
 
The MRI technique uses magnets and radiowaves to construct a picture of the brain 
on a computer.  Before the scan begins, you will be asked to remove any magnetic 
metals that you may be wearing.  For the procedure, you will be asked to lie on a 
padded bed that will be moved into a tunnel-like machine for the MRI scan of your 
brain. Since you will be inside the machine during the scan, and a screen will be in 
place for viewing the visual images, you may not be able to see the technicians 
operating the machine or the investigators.  However, there is an intercom system 
that will allow you to talk with them at any time.  If you feel uncomfortable during 
the scan and you wish to discontinue the procedure, you will be taken out of the 
machine at your request. 
 
We will obtain a series of MRI scans, separated by short breaks, and the entire 
procedure will take approximately one hour.  During the scans we will ask you to 
carry out a variety of tasks.  You should try to remain as still as possible during each 
scan.  Movement will not be dangerous to you in any way, but would blur the 
picture of your brain.  You will hear moderately loud knocking or beeping during the 
scan when the MRI machine is in operation.  Although you may find this to be 
unsettling, the machine cannot hurt you in any way.  
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Please note:  Prior to your first scan you will also be required to sign an additional 
consent form required by Baycrest hospital which provides similar information about 




Brain scans will be taken at: 
i. Week 0 (prior to the exercise programme)  
ii. Week 12 (after completion of the exercise programme). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Phobia of small confined spaces  
i. Metal Implants, pieces of shrapnel, aneurysm clips, or wires in your head. etc.  
ii. Implanted Pace Maker 
iii. Pregnant 
iv. Inability to get to the scanner at Rotman Baycrest*.    
 
*We will compensate you for your parking and gasoline costs but you will need to be 
able to drive yourself or have someone else able to drive you in order to participate. 
 
4. Risks and Discomforts  
The MRI scan is not associated with any known risks to your health and there is no 
evidence that there will be either short-term or long-term side effects. Participants 
undergoing fMRI may feel uncomfortable or claustrophobic in the confined space.  
Furthermore, the machine makes a loud noise which some people may find 
distressing.  There will be someone with you at all times during the brain imaging, in 




E. EXERCISE PROGRAMME 
 
1. Description  
You will complete an exercise safety screening questionnaire called the Par-Q.  If 
there are any concerns about the safety of your participation, you will have the 
option of withdrawing or getting your family doctor to complete the ParMed-X to 
ensure it safe for you to exercise. 
Once enrolled and baseline assessments have been carried out you will commence a 
12 week exercise programme as part of the Mental Health Treatment Programme.  
The exercise sessions will take place at the Durham Family YMCA, located just down 
the road from the Lakeridge Health Day Programme.  All sessions will be in groups of 
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2 to 5 participants and will be supervised by the Exercise Supervisor for three 
sessions per week and you must be prepared to commit to attending at least 80% of 
the exercise sessions. The role of the supervisor will be to give you verbal 
encouragement, monitor you for any possible adverse effects and provide aid as 
needed, and to help you monitor your heart rate to ensure they you are working at 
the correct intensity.  The exercise prescription will be individualized based on your 
starting fitness levels.  One session per week will be aerobic exercise only, and the 
remaining two will be resistance exercise followed by a shorter aerobic bout. Based 
on your experience and ability, one resistance exercise will be selected from each of 
six categories – horizontal push, anterior lower body, vertical pull, posterior lower 
body, horizontal pull, and vertical push in order to establish a balanced, whole-body 
exercise prescription. Exercises will be changed after four weeks, to avoid 
adaptation. The aerobic bout following resistance sessions will be 20 minutes in the 
first week, and 30 minutes in subsequent weeks. Sessions containing a resistance 
component will be performed at least 24 hours apart. All sessions begin with a ten-
minute aerobic warm-up, and are supervised by a kinesiologist. Participants are 
advised to bring a drink bottle and keep well hydrated. Opportunities will be 
provided to make up missed sessions. In order to provide a transition out of the 
exercise programme, in weeks 9 and 12, participants will have one supervised 
session per week.  
 
2. Timeframe 
i. 3 one hour sessions per week for 12 weeks  
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Already exercise more than 20 minutes, three times per week  
ii. Physical conditions such as heart disease, or exclusions identified based on ParQ 
or ParMedX questionnaires. 
iii. I am unable to attend at least 80% of the exercise sessions 
 
4. Risks and Discomforts  
You may experience some physical discomfort both during exercise or stretching and 
following exercise or stretching, such as muscle soreness.  There is a small risk of 
injury occurring during any exercise programme; however, the kinesiologists 
involved are trained in modifying exercise programmes to minimize this risk and you 
will be supervised at all times.  There will be someone with you at all times during 
the exercise sessions, in case you should experience any adverse effects. 
 
RESULTS 
You will also be given a log to keep track of each procedure required from you. This log is to be 




Once the information has been collected from all participants, the questionnaire responses will 
be examined to establish the effect of exercise on depression, cortisol secretion, several 
biomarkers and coping self-efficacy, and fMRI results will be analyzed and a report will be 
written up.  A short version of this report will be available to participants who would like a 
copy.  You can indicate at the bottom of the consent form whether you would like to receive 
your report by email or by regular mail. 
 
If you have depression and you experience any worsening of your depression during your 
participation in the study, you will be referred immediately to the treatment team at Lakeridge 
Mental Health.  If you are concerned about any aspect of your participation, do not hesitate to 
contact the researchers at the numbers provided. 
 
Compensation for Participation 
There will be no direct compensation for participating in this research study, although you will 





Despite efforts to keep your personal information confidential, absolute confidentiality cannot 
be guaranteed.  Your personal information may be disclosed if required by law.  This legal 
obligation includes a number of circumstances, such as suspected child abuse and infectious 
disease, elevated risk or harm to you or others, and a court order by authorized agencies.  For 
your information, the research consent form will be inserted in the patient health record. 
 
Medical records that contain your identity will be treated as confidential in accordance with 
Ontario’s privacy legislation, the Personal Health Information Protection Act, 2004.  
 
The only people who will be accessing your patient records are the Lakeridge clinicians involved 
in your treatment.  The other information collected by the researchers is separate and will be 
seen only by the researchers and all identifying information will be removed in any 
publications.   
 
The Lakeridge Health Corporation Research Ethics Board and the University of Ontario Institute 
of Technology Research Ethics Board may review records related to the study for quality 
assurance purposes, as it oversees the conduct of this study at Lakeridge Health.  
 
Please read the following before signing the consent form and remember to keep a copy for 
your own records. 
 
By signing this form, I agree that: 
 
• The study has been explained to me.  All my questions were answered to my satisfaction. 
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• The possible harms and discomforts and the possible benefits (if any) of this study have been 
explained to me. 
• I know about the alternatives to taking part in this study.  I understand that I have the right 
not to participate and the right to stop at any time.  The decision about whether or not to 
participate will not affect my health care at Lakeridge Health. 
• I am free now, and in the future, to ask any questions about the study. 
• I have been told that my medical records will be kept confidential, except where release of 
information is required by law  
• I understand that no information that would identify me, will be released without asking me 
first, unless the disclosure is required by law 
• I hereby consent to participate.   
 
I have completed the individual procedure assessments on pages 3 to 8 of this form and 
hereby consent to participate in the following procedures (please tick the box): 
 
1) Questionnaire completion  
2) Blood samples 





Information gathered in this research study may be published or presented in public forums; 
however your name and other identifying information will not be used or revealed.  We hope 
the information learned from this study will benefit other people and support the use of 
exercise as a treatment for depression in future patients.  
You will be provided with a summary of findings at the end of the study, if you so desire.  We 
will do our best to explain the findings to you in way that you understand and what these 
changes mean.  Often in research we don’t get the findings we expect.  This is often because we 
didn’t study enough participants or the changes are of a different nature then we 
expected.   This is okay and still makes a very important contribution to science and to our 
understanding of depression. If you are concerned about any of the study findings or you would 
like more information, please contact Dr. Bernadette Murphy or Dr. Paul Yielder to discuss. 
 
 
Please advise us of your preferable format for communication (check one and provide details in 




Please indicated by ticking the box whether you wish to receive your summary 










Participant Printed Name_________________________________  
 
 
I, the undersigned, have fully explained the relevant details of this research study to the 
participant named above and believe that the participant has understood and has knowingly 


































Appendix 6: HADS 
 
When you answer the following questions we ask that you please chose only one response for each 
question and give the response that immediately comes into your head.  
Place a tick or mark beside the answer that best relates to how you feel.  
 
I feel tense or ‘wound up’: 
o Most of the time 
o A lot of the time 
o From time to time, occasionally 
o Not at all 
 
I still enjoy the things I used to enjoy: 
o Definitely as much 
o Not quite so much 
o Only a little bit 
o Hardly at all 
 
 
I get a sort of frightened feeling as if something 
awful is about to happen: 
o Very definitely and quite badly 
o Yes, but not too badly 
o A little, but it doesn‟t worry me 
o Not at all 
I can laugh and see the funny side of things: 
o As much as I always could 
o Not quite so much now 
o Definitely not so much now 
o Not at all 
 
 
Worrying thoughts go through my mind: 
o A great deal of the time 
o A lot of the time 
o From time to time, but not too often 
o Only occasionally 
 
 
I feel cheerful: 
o Not at all 
o Not often 
o Sometimes 
o Most of the time 
 
I can sit at ease and feel relaxed: 
o Definitely 
o Usually 
o Not often 
o Not at all 
 
 
I feel as if I am slowed down: 
o Nearly all the time 
o Very often 
o Sometimes 
o Not at all 
 
I get a sort of frightened feeling like 
‘butterflies’ in the stomach: 
o Not at all 
o Occasionally 
o Quite often 
o Very often 
 
 
I have lost interest in my appearance: 
o Definitely 
o I don‟t take as much care as I should 
o I may not take quite as much care  
o I take just as much care as ever 
 
 
I feel restless as I have to be on the move: 
o Very much indeed 
o Quite a lot 
o Not very much 
o Not at all 
 
I look forward with enjoyment to things: 
o As much as I ever did 
o Rather less than I used to 
o Definitely less than I used to 
o Hardly at all 
 
I get sudden feelings of panic: 
o Very often indeed 
o Quite often 
o Not very often 
o Not at all 
 




o Not often 
o Very seldom 
 
 
(Modified from Zigmond & Snaith, 1983) 
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Appendix 8: PSQI 
Sleep Quality 
Instructions: The following questions relate to your usual sleep habits during the past two weeks 
ONLY. Your answers should indicate the most accurate reply for the majority of days and nights 
in the past 2 weeks. Please answer all questions. 
1. During the past 2 weeks, when have you usually gone to bed at night? 
  USUAL BED TIME______________________________ 
2. During the past 2 weeks, how long (in minutes) has it usually taken you to fall asleep each 
night? 
  NUMBER OF MINUTES__________________________ 
3. During the past 2 weeks, when have you usually gotten up in the morning? 
  USUAL GETTING UP TIME_______________________ 
4. During the past 2 weeks, how many hours of actual sleep did you get at night? (This may be 
different than the number of hours you spend in bed) 
  HOURS OF SLEEP PER NIGHT____________________ 
For each of the remaining questions, check the one best response. Please answer all questions. 
 
5. During the past 2 weeks, how often have you had 


































































Cannot get to sleep within 30 minutes     
Wake up in the middle of the night or early morning     
Have to get up to use the bathroom     
Cannot breathe comfortably     
Cough or snore loudly     
Feel too cold     
Feel too hot     
Had bad dreams     
Have pain     
Other reason(s) please 
describe______________________________ 
    
 
6. During the past 2 weeks how would you rate your sleep quality overall? (please circle) 




7. During the past 2 weeks, how often have you taken medicine (prescribed or “over the 
counter”) to help you sleep? (Please circle) 
Not during the  Less than      Once or        Three or more 
past 2 weeks   once a week      twice a week      times a week 
 
8. During the past 2 weeks, how often have you had trouble staying awake while driving, eating 
meals, or engaging in social activity? (Please circle) 
Not during the  Less than      Once or        Three or more 
past 2 weeks   once a week      twice a week      times a week  
 
9. During the past 2 weeks, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? (Please circle) 
No problem   Only a very   Somewhat      A very  
at all    slight problem  of a problem     big problem 
 
10. Do you have a bed partner or share a room? 
No bed partner or do not share a room  ______________ 
Partner/flat mate in other room   ______________ 
Partner in the same room, but not same bed  ______________ 
Partner in the same bed    ______________ 
 



































































Loud snoring     
Long pauses between breaths while asleep     
Legs twitching or jerking while you sleep     
Episodes of disorientation or confusion during sleep     
Other restlessness while you sleep (please describe)     
 









SALIVA COLLECTION METHOD 
 
Exercise and Brain Function Study 
 
During this study, you will be collecting saliva samples to be tested for the stress hormone cortisol.  Levels of 
cortisol change in a predictable way throughout the day.  Because of this, you need to collect saliva samples at 
the exact times instructed for the results to be accurate.  Also, activities such as eating and drinking can affect 
your saliva, so please make sure you follow the instructions for how to collect your sample.  Please tell us if you 
have any sores in your mouth. 
 
Week 0 and Week 12 
 You will be given two Salimetrics Oral Swab devices and an insulation pack at your orientation session 
at the UOIT fitness centre 
 You will be collecting saliva samples on the WEDNESDAY following this appointment 
 These vials will be labelled “Weds – waking” , “Weds – 30 min” 
 Collect ONE sample using the two “Weds – waking” vials immediately on awakening on Wednesday 
 Remove swab from tube leaving tube insert in place. Place into mouth under tongue. Keep in place for 
1-2 minutes. 
 Collect ONE more sample in the same way 30 min later in the “Weds– 30min”vial 
 DO NOT consume caffeinated drinks, eat, brush teeth, smoke or use steroid creams/inhalers between 
collection of first two samples 
 Freeze both samples immediately in your freezer 





Appendix 10: 11-item exercise self-efficacy 
Barriers Efficacy Scale 
 
The items below reflect common reasons preventing people from participating in exercise 
sessions or in some cases, dropping out or quitting exercise altogether. Using the scale below 
please indicate how confident you are that you could exercise in the event that any of the 
following circumstances were to occur. 
 
 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
For example, if you have complete confidence that you can continue to exercise, even if you are 
bored by the activity, you should circle 100%. However, if you are absolutely sure that you could 
not exercise if you failed to make or continue to make progress you would circle 0% (No 
confidence at all). 
 
I believe I can exercise 3 times per week if: 
 
 The weather is very bad (hot, humid, rainy, snow, cold). 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I was bored by the program or activity. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I was on vacation. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I felt pain or discomfort when exercising. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I had to exercise alone. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
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No confidence at all        Somewhat confident   Completely confident 
 
 
 Exercise was not enjoyable or fun. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 It became difficult to get to the exercise location. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I didn‟t like the particular activity program that I was involved in. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 My work schedule conflicted with my exercise session. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I felt self-conscious about my appearance when I exercised. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 The instructor did not offer me any encouragement. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
 
 I was under personal stress of some kind. 
0%  10%   20%   30%   40%   50%   60%   70%   80%   90%   100%  
No confidence at all        Somewhat confident   Completely confident 
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Appendix 11: 6-item exercise self-efficacy 
SELF EFFICACY FOR EXERCISE SCALE 
The following questions regard how confident you are that you could perform exercise three 
times per week for the next four weeks without quitting and accurately completing the prescribed 
workload (40 minutes, 3 times per week).  You would indicate 100% if you are confident you 
can continuously exercise for at least 40 minutes involving aerobic and weights training, three 
times per week. 
1. I am able to continue to exercise three times per week performing all prescribed repetitions, 
for  40+ minutes without quitting for the NEXT WEEK  
0% 10%  20%  30%  40%  50%  60%  70%  80%  90%  100%  
  
2.  I am able to continue to exercise three times per week performing all prescribed repetitions, 
for 40+ minutes without quitting for the NEXT TWO WEEKS  
0% 10%  20%  30%  40%  50%  60%  70%  80%  90%  100%  
 
3.  I am able to continue to exercise three times per week performing all prescribed repetitions, 
for 40+ minutes without quitting for the NEXT THREE WEEKS  
0% 10%  20%  30%  40%  50%  60%  70%  80%  90%  100%  
  
4. I am able to continue to exercise three times per week performing all prescribed repetitions, 
for 40+ minutes without quitting for the NEXT FOUR WEEKS   
0% 10%  20%  30%  40%  50%  60%  70%  80%  90%  100% 
 
(Modified from McAuley, 1993) 
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Professor Bernadette Murphy 
Head Kinesiology Specialization and Director of Health Sciences 
Faculty of Health Sciences 
University of Ontario Institute of Technology 
2000 Simcoe St North,  
Oshawa, Ontario. 
L1H 7K4 
Phone: (905) 721-8668 ext 2778 
email: Bernadette.Murphy@uoit.ca  
Fax: 905 721 3179   
April 26, 2012 
Dear Dr. __________________________________, 
 
Your patient, _________________________________________, wishes to participate in 
a study entitled “Mechanisms by which exercise promotes hippocampal function in both 
depressed and non-depressed individuals” being run by UOIT Kinesiology in conjunction 
with the Lakeridge Mental Health Day Treatment program. 
 
This research study is being conducted to study the effect of exercise on levels of the 
stress hormone cortisol and a number of other biomarkers known to be altered in 
depression. We will also be looking at the way their brain functions during certain 
memory tasks.  We are also interested in how exercise may affect the intensity of 
depression symptoms.  These will be assessed over the course of a 12 week structured, 
supervised exercise program, in addition to the treatment they are already receiving as 
part of the Lakeridge Mental Health Day Treatment program.  The study will also involve 
two visits to a special MRI scanner at the Rotman Baycrest hospital.    
 
In order to be eligible for this study participants can be a man or woman aged 18 to 50 
years.  They must also currently be sedentary (i.e. exercising less than 3 times weekly for 
less than 20 minutes at a time).   The 12 week exercise programe will be supervised by 
CSEP certified personal trainers, with heart rate monitoring for the aerobic component. 
Your patient answered yes to one or more questions on the PAR-Q which means that they 
need physician clearance prior to commencing exercise.  We have attached a copy of the 
Par Med X which needs to be completed before your patient can join the study. In the 
interests of participant safety if they have any absolute or relative contraindications they 
are not eligible.  However, we can certainly adjust the exercise prescription to 
accommodate those with minor musculoskeletal issues or individuals with well controlled 
hypertension as examples. 
 
If you have any additional questions, please contact the research co-ordinator, Joanne 




Bernadette Murphy, PhD 
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Appendix 14: Blood collection log 
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Appendix 15: Resistance exercise options 
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